AU2004293127A1 - Anti-cancer agents - Google Patents

Description

WO 2005/051901 PCT/AU2004/001667 ANTI-CANCER AGENTS Field of the Invention 5 The present invention relates to anti-proliferative and anti-cancer agents, particularly those anti-cancer agents that have a core framework structurally related to or derived from amino acid or amino acid like frameworks such as cysteine or 7-substituted 2-amino-heptanoates and which may be utilised in 10 cancer and antiproliferative therapies either on their own or in combination with other anti-cancer agents. The invention further provides pharmaceutical and/or veterinary compositions containing the anti-cancer agents of the invention that may be used in the treatment of cancers. The invention further relates to the use of the anti-cancer agents of the invention in the preparation of medicaments 15 for the treatment of cancer and to methods of treatment of cancer using the anti-cancer agents or compositions containing them. Background of the Invention 20 Cancer is one of the leading causes of death in the modern world with the incidence of cancer related deaths rising with the ageing population. At the present time there are three main treatment strategies for cancer: (1) removal of the cancer by surgery (where possible), (2) use of radiotherapy, or (3) use of combination chemotherapy. With some cancer types a combination strategy is 25 used in which as much of the cancerous tissue being removed by surgery as possible followed by a course or courses in chemotherapy to eliminate any remaining cancer cells. A major dose-limiting problem associated with most chemotherapy is the general toxicity of the drugs currently available. Anti cancer drugs today are typically general cytotoxins with little selectivity in their 30 killing action for cancer cells over normal human cell types. This lack of selectivity leads to a significant number of adverse side effects in patients who undergo chemotherapy.

WO 2005/051901 PCT/AU2004/001667 2 The development of truly selective cancer chemotherapy in which a drug specifically destroys malignant cells without damaging normal cells remains an elusive goal. A further promising strategy (Marks et al., 1994; Rifkind et al., 1996, Leszczyniecka et al., 2001; Vigushin et al., 2002)is the use of agents that can 5 differentiate cancer cells to either a non-proliferating or normal phenotype, an approach that has the potential to be tissue-specific and avoid side effects of current drugs. However, most compounds known to differentiate tumour cancer cells are of low potency in cell culture and tend to be non-selective in vivo, where differentiation is reversible or drug resistance is a problem. A few natural 10 products (e.g. trichostatins (Tsuji et al., 1976; Yoshida et al., 1990) and trapoxins (Kijima et al., 1993)) and close analogues display potent differentiating properties on tumour cells in vitro, but they display little or no selectivity being cytotoxic to both normal and cancer cells and most such compounds are ineffective in vivo due to low bioavailability and rapid metabolism. Representative of the structural 15 formulae of these compounds are Trichostatin A and Trapoxin B as shown below. N g 2 0 0 H N OH H NN NH10 01 Trichostatin A Trapoxin B The differentiating agents discussed above are now known to cause 20 hyperacetylation of histones, by inhibiting enzymes known as histone deacetylases (HDACs). It is also clear that multi-protein complexes incorporating HDACs are involved in cell cycle regulation and gene expression. HDACs are involved in modulating chromatin structure by facilitating unpackaging of chromosomal DNA and 'loosening up' histones to permit transcription. Histones 25 of the nucleosome are normally tightly wrapped in DNA and linked together, like beads on a string by DNA. Nuclease-mediated digestion of both the linking and WO 2005/051901 PCT/AU2004/001667 3 wrapping DNA from histones enables gene expression. Unwrapping exposes the octameric histone core, which dissociates into component histones H2A, H2B, H3, H4, etc. Histones are reversibly acetylated on the e-amino side chain of Lys residues as shown below, and interactions between deacetylated histones and 5 DNA are crucial for gene expression. Histone acetylation and other modifications regulate gene expression by reducing access of transcription factors to DNA. The degree of histone acetylation is regulated by histone acetyl transferases (HATs; 3 groups), deacetylases (HDACs, 16 genes), and their inhibitors, which regulate the cell cycle and consequently hold promise for development of 10 anticancer drugs. Studies by the current applicants and others (WO9855449; Cress et al., 2000; Marks et al., 2001) indicate that HDAC inhibitors cause tumor regression in vivo without damaging DNA.

NH

3 HDACs HATs 15 At least eleven HDACs have been identified and, although it is unknown to what extent these enzymes exercise redundant or specific functions, subtle sequence differences between HDACs suggest that it may be possible to develop inhibitors that are selective for specific HDAC enzymes. Crystallographic 20 studies on the histone deacetylase-like protein (HDLP) isolated from Aquifex aeolicus indicate that the active site residues of these enzymes are highly conserved, with most variability at the entrance to this cleft, particularly on the solvent exposed rim of the active site that accommodates the lysine side chain. Furumai et al. (2001) has shown that a carboxylic acid analogue of trapoxin, 25 which is a poorer zinc ligand, is still potent with ICo of 100 nM probably due to the existence of significant interactions with the protein surface at the entrance to the HDAC active site.

WO 2005/051901 PCT/AU2004/001667 4 Notwithstanding the potential of the above compounds and analogues thereof as anti-cancer agents, there is the need to develop further potential anti-cancer agents that provide viable alternatives to the known treatments. In particular there is the need to develop anti-cancer agents that have therapeutic efficacy in 5 vivo and which show some degree of selectivity for cancer cells. A further advantage would be obtained if such compounds were also able to revert the transformed morphology of cancer cells to that of a non-proliferating phenotype. Herein we describe a facile entry to new antitumor compounds designed to 10 reproduce and modify protein surface-binding interactions made by hydrophobic substituents found in highly potent naturally occurring HDAC inhibitors such as trichostatin and trapoxin B. The applicants have conducted investigations to design a consensus structural scaffold for the development of such antitumour agents. The resulting scaffold provides a convenient source of assymetry to 15 append functionality in several directions and is amenable to combinatorial synthesis. The applicants have used toxicity/selectivity for tumor cells as the primary screen to guide the compound development rather than directly measuring inhibition of specific HDACs, since protein acetylation/deacteylation appears to be a general cell signalling device with many protein/DNA targets for 20 HDAC inhibitors. However, because HDAC inhibition does correlate with the potency of the compounds, if not selectivity, a general HDAC-inhibitor pharmacophore has been used to aid the design of active compounds. The resulting compounds based on the scaffold are cytotoxic antitumour agents 25 that typically inhibit histone deacetylases, cause hyperacetylation of histones, p21 induction, and transform various surviving cancer cells to more normal phenotypes. In particular we describe several compounds derived from the common structural scaffold that demonstrate cytotoxicity selective for proliferative cancer over normal cell lines. 30 Throughout this specification reference may be made to documents for the purpose of describing various aspects of the invention. However, no admission is made that any reference cited in this specification constitutes prior art. In WO 2005/051901 PCT/AU2004/001667 5 particular, it will be understood that the reference to any document herein does not constitute an admission that any of these documents forms part of the common general knowledge in the art in Australia or in any other country. The discussion of the references states what their authors assert, and the applicant 5 reserves the right to challenge the accuracy and pertinency of any of the documents cited herein. Summary of the Invention 10 The present invention provides a compound having the formula (1), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

R

6 o R7, N

Z-R

1 -M (I) 15 wherein Z is S or CH 2 ; 20 R 1 is a linking moiety; M is a zinc binding moiety containing at least one heteroatom;

R

6 is selected from the group consisting of H, optionally substituted alkyl, 25 optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; X is selected from the group consisting of: WO 2005/051901 PCT/AU2004/001667 6 0 S 0 II II || -CH2- -- C- -C- and -S Y is selected from the group consisting: of -NR 4

R

5 , -OR 4 , -SR 4 , -CH 2

R

4 , 5 CHR 4

R

5 , C(R 4

)

2

R

5 , PHR 4 and PR4R 5 , wherein R 4 is a group of formula: O0 H\ t-(R 8 )p-(R 9 )qC-N (Rio), r 10 wherein R 8 , RE and R 10 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally 15 substituted heterocycloalkyl; p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1; 20 R 5 is H or a group of formula: O0 H\ t(Rjj)t-(R12).ulC-N v (R13). wherein R 11 , R 12 and R 113 are each independently selected from the 25 group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, WO 2005/051901 PCT/AU2004/001667 7 optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of 5 t, u and w is 1;

R

7 is a group of formula: (R16)z-(R15)y-(R14)xC 10 wherein R 1 4 , R 15 and R 16 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally 15 substituted heterocycloalkyl, x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1. 20 In one particular embodiment of the invention the compound having the formula (1) is based on cysteine. Accordingly, the embodiment of the invention provides a compound of formula (Ila), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof: R6 0 R7, . N 25 S- R-M (Ila) wherein R 1 , R 6 , R 7 , M, X and Y are as defined above for the compound of formula (I). 30 In another embodiment of the invention the compound having the formula (1) is based on 7-substituted 2-amino-heptanoates. Accordingly, the embodiment of WO 2005/051901 PCT/AU2004/001667 8 the invention provides a compound of formula (Ilb), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

R

6 o

R

1 -M (Ilb) 5 wherein R 1 , R 6 , R7, M, X and Y are as defined above for the compound of formula (1). As with all chemical families there are a number of preferred embodiments within the scope of the general formula. In particular it is preferred that the 10 linking moiety R, has between 1 and 9 atoms in a normal chain, preferably between 1 and 4 atoms in a normal chain. It is also preferred that the group Y is a group of formula -NR 4

R

5 . 15 It is preferred that the zinc binding moiety containing a heteroatom is a hydroxamic acid derivative, preferably a group of formula -C(O)-NR 2 -OR3 where R 2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group and R 3 is H, optionally substituted alkyl, optionally substituted alkenyl, 20 optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group. Accordingly in a preferred embodiment the present invention provides a compound having the formula (lli), or a pharmaceutically acceptable derivative, 25 salt, racemate, isomer or tautomer thereof: WO 2005/051901 PCT/AU2004/001667 9 6 o

R

7 X X'N

N'R

5 N zR4 /R Z OR3 R1--C(O)-N R2 (Ill) 5 wherein

R

1 is optionally substituted C 1

-C

4 alkyl, optionally substituted C-C 4 alkenyl or optionally substituted C-C 4 alkynyl;

R

2 is H, optionally substituted alkyl, optionally substituted alkenyl, 10 optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group;

R

3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryi or an oxygen 15 protecting group;

R

4 is a group of formula: (Rs)p- (R 9 )qC - (R10) r 20 wherein R 8 , R 9 and R 1 0 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally 25 substituted heterocycloalkyl; WO 2005/051901 PCT/AU2004/001667 10 p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1;

R

5 is H or a group of formula: 5 O H (R11)t-(R12)u C-N (RI 3 )w wherein R 11 , R 12 and R 113 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted 10 alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of 15 t, u and w is 1.

R

6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; 20 X is selected from the group consisting of 0 S 0

-CH

2 - -C- -C- and -- S 0 25 R 7 is a group of formula: (R16)z-(RI5)y-(R14)xC- WO 2005/051901 PCT/AU2004/001667 11 wherein R 1 4 , R 1 5 and R 16 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally 5 substituted heterocycloalkyl; x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1. 10 Even within this preferred subset of compounds there are a number of preferred values for each of the variables in the structural formula given above. For example it is preferred that R 1 is optionally substituted CrC4 alkyl, more preferably optionally substituted C2-C3 alkyl, even more preferably optionally substituted C3 alkyl, most preferably propyl. 15 It is preferred that R 2 is either H, optionally substituted Cr-C4 alkyl or a nitrogen protecting group, more preferably H or a nitrogen protecting group, most preferably H. 20 It is preferred that R 3 is either H, optionally substituted CrC4 alkyl or an oxygen protecting group, more preferably H or an oxygen protecting group, most preferably H. Particularly preferred compounds of formula (Ill) are therefore those of formula 25 (Ilia) and (IlIb).

R

6 o R7, N N R5 -R4 S NH-OH 0 (Ilia) WO 2005/051901 PCT/AU2004/001667 12

R

6 o R7,X NN

R

5 X'NN R4 NH-OH 0 (Illb) In the compounds of the invention it is preferred that X is a carbonyl group. 5 It is preferred that Rq is either H or optionally substituted alkyl, preferably H. It is preferred that R 6 is either H or a nitrogen protecting group, most preferably H. 10 In one preferred embodiment the group R 4 is of the formula O H || 1

-R

8

-R

9

-C-N-R

1 0 , 15 wherein R 8 , R 9 and R 1 0 are as defined above. In this embodiment it is particularly preferred that R 4 is of the formula: O H -(optionally substituted alkyl)- (optionally substituted aryl) - C-N- (optionally substituted aryl) 20 In the most preferred form of this embodiment R 4 is a group of the formula. (R)n (R)m -CH2 -- C WO 2005/051901 PCT/AU2004/001667 13 wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, 5 cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, 10 arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; 15 n is 0-4, and m is 0-5. In an another preferred embodiment of the invention R 4 is selected from the 20 group consisting of: optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted 25 heterocycloalkylalkyl, optionally substituted aryl alkenyl, optionally substituted heteroaryl alkenyl, optionally substituted cycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted aryl alkynyl; optionally substituted heteroaryl alkynyl optionally substituted cycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl. 30 In this embodiment it is particularly preferred that R 4 is selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkyl alkyl, optionally WO 2005/051901 PCT/AU2004/001667 14 substituted alkyl aryl, optionally substituted alkyl heteroaryl, optionally substituted alkyl heterocycloalkyl. In a most preferred embodiment of the invention R 4 has one of the following 5 formulae. (R)m (R)m (R)m -j alkyll alkyl H (R)m (R)m (R)m Het +alkenyl alkenyl H Wherein each R is independently selected from the group consisting of alkyl, 10 alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, 15 nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphnyl, 20 carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; and each m is from 0-5. 25 In the compounds of the invention it is preferred that R 7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted WO 2005/051901 PCT/AU2004/001667 15 heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heteroaryl alkyl, optionally substituted cycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted aryl alkenyl, optionally substituted hetero alkenyl, optionally substituted cycloalkyl alkenyl, optionally substituted 5 heterocycloalkyl alkenyl, optionally substituted aryl alkynyl, optionally substituted heteroaryl alkynyl, optionally substituted cycloalkyl alkynyl, and optionally substituted heterocycloalkyl alkynyl. It is even more preferred that R 7 is optionally substituted aryl, optionally 10 substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted alkenyl, and optionally substituted aryl alkenyl. It is most preferred that R 7 has one of the following formula: 15 (R)p (R)p (R)p $4 6 - alkyl alkyl (R)p (R)p (R)p alkenyl- alkenyl wherein each R is independently selected from the group consisting of alkyl, 20 alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, 25 nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, WO 2005/051901 PCT/AU2004/001667 16 arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; 5 and each p is from 0-5. A number of specific compounds are particularly preferred. The structures of particularly preferred compounds are described in Tables 1 and 5 (compounds 10 of examples 22-58), Tables 2 and 6 (compounds of examples 59-96), Tables 3 and 7 (compounds of examples 97-102), Table 8 (compounds of examples 103 121) and Tables 4 and 9 (compounds of examples 122-168). Some preferred compounds include the following: 15 0 0 HN 0 - NH NDS NH-OH 00 0 0 HN O NH Br S NH-OH 0 WO 2005/051901 PCT/AU2004/001667 17 0 0 HN N-O NH NH NH-OH 0 0 / NH 0 NHI-OH 0 5 -N N ONH

NH

-- N NH O NH-OH 0 10 TO "NH 0"O - NH O NH-OH 0 10 WO 2005/051901 PCT/AU2004/001667 18 -NNH O NH-OH 0 - N H0 OH O NH-OH 0 5 -N NH NH O NH-OH 0 O O HN NH NH-OH 10 All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs), such as WO 2005/051901 PCT/AU2004/001667 19 those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of 5 the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Particularly preferred compounds are those compounds of formula (Ill) that 10 have a potency of cytotoxicity of ICro 10 M against the MM96 melanoma cells. More preferred are those compounds of formula (ll) that have a potency of IC5a 10 pM against the MM96 melanoma cells and a Selectivity Index of 1.5. Even more preferred compounds are those of formula (Ill) that have a potency of IC5o 1 piM against the MM96 melanoma cells and a Selectivity 15 Index of 3. Most preferred compounds are those of formula (Ill) that have a potency of IC50 0.5 pM against the MM96 melanoma cells and a Selectivity Index of 4. Exemplary examples include compounds of examples 24, 40, 48, 59, 66, 67, 100, 123, 124, 125, 126, 130, 131, 132, 133, 137, 138, 146, 148, 160, 162 and 166. 20 The inventor's studies have shown that compounds of the present invention are cytotoxic anti-cancer agents. Accordingly, the present invention also provides a method for the treatment of cancer in an animal, the method including the step 25 of administering to the animal in need of such treatment an effective amount of a compound having the formula (1), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

R

6 o

R

7 - N Z-RI-M 30 (I) WO 2005/051901 PCT/AU2004/001667 20 wherein Z is S or CH 2 ; 5

R

1 is a linking moiety; M is a zinc binding moiety containing at least one heteroatom; 10 R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; X is selected from the group consisting of: 15 0 S 0 -CH -- C -C- and -S 0 Y is selected from the group consisting: of -NR 4

R

5 , -OR 4 , -SR 4 , -CH 2

R

4 ,

CHR

4

R

5 , C(R 4

)

2

R

5 , PHR 4 and PR 4

R

5 , 20 wherein R 4 is a group of formula: O0 H r(R 8 )p-(R 9 )jAC-N (R1o)s r 25 wherein R 8 , R 9 and Rio are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally WO 2005/051901 PCT/AU2004/001667 21 substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; p, q, r and s are each independently 0 or 1, provided that at least one of 5 p, q or s is 1;

R

5 is H or a group of formula: O0 H\

(R

1 R2)u C- v(R1 3 )w 10 wherein R 11 , R 12 and R 113 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally 15 substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1; 20 R 7 is a group of formula: (R16)z-(RI 5)y-(R14)xwherein R 14 , R 15 and R 16 are independently selected from the group 25 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl, 30 x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1.

WO 2005/051901 PCT/AU2004/001667 22 In a preferred embodiment of the method of the invention the animal is a human. The compound of the invention may be administered in any suitable form well known in the art including oral administration in the form of a liquid, syrup, tablet or the like, by injection or by intravenous infusion. It is preferred 5 that the compound is administered by intravenous infusion. The present invention also provides pharmaceutical and/or veterinary compositions containing one or more of the compounds of the invention and a pharmaceutically acceptable, carrier, diluent or excipient. These compositions 10 may be used in the methods of treatment discussed previously. In a further aspect the invention provides the use of the compounds of the invention as hereinbefore described for the preparation of a medicament for the treatment of cancer. 15 Description of the Figures Figure 1. Acetylation of Histones. MM96L cells were treated with 5 ptg/mL of test compounds for 8 hours, before harvest and analysis of histone H4 20 acetylation by Triton-acetic acid-urea gel (Saito et aL, 1991; Qiu et al., 1999). Lane 1: untreated. Lane 2: compound of example 22 Lane 3: compound of example 40. Lane 4: TSA. Non-acetylated (A), mono-acetylated (B), di acetylated (C), tri-acetylated (D) and tetra-acetylated (E) histone H4 are indicated. 25 Figure 2. Acetylaton of histones MM96L cells were treated with 5 Ig/ml of various compound for 8 hr, before harvest and analysis of histone H4 acetylation by Triton-acetic acid-urea gel as previously described (Saito et al., 1991; Qiu et al., 1999). Lane 1: untreated: lane 2: Compound of example 73; 30 lane 3: Compound of example 40; lane 4: TSA. Non-acetylated (A), mono acetylated (B), di-acetylated (C), tri-acetylated (D) and tetra-acetylated (E) histone H4 are indicated.

WO 2005/051901 PCT/AU2004/001667 23 Figure 3. Induction of p21 expression. MM96L cells were treated with the compound of example 15 (10 pg/mL) and total RNA was isolated from cells, reverse transcribed using SuperScript II and oligo-dT primer, and cDNA amplified by PCR using primers specific for p 21 WAF1/Cip1 and GAPDH. Lane 1, untreated; 5 lane 2, 16 hours treatment; lane 3, 24 hours treatment; lane 4, RT-PCR negative control. Quantitation of p 2 1 WAF1/Cip1 induction was performed by densitometric analysis using ImageQuaNT 4.2 software (Molecular Dynamics, Sunnyvale, CA) following normalisation to GAPDH product intensity. Expression of p 21 WAF1/Cip1 was increased 2.1-fold above that of untreated cells at both the 16 and 24 hr time 10 points. Figure 4. Induction of p21 expression MM96L melanoma cells were treated with 2 compounds at a concentration of 10 ptg/ml, and total RNA was isolated following 16 and 24 hrs, as described in Materials and Methods. Semi 15 quantitative RT-PCR was performed on the total RNA samples. Induction of mRNA for p 21 WAF1ICip1 was seen after 16 hrs treatment for both compound of example 24 and compound of example 67. Figure 5. Morphological Reversion After 24 hours. (a) Untreated normal 20 melanocytes; (b) Normal melanocytes treated with compound of example 40 (10 pg/mL); (c) Untreated melanoma cells (MM96L); (d) MM96L treated with compound of example 40 (10 pg/mL). Figure 6. Morphological Reversion After 24 hours. (a) Untreated normal 25 melanocytes; (b) Normal melanocytes treated with compound of example 67 (10 pg/mL); (c) Untreated melanoma cells (MM96L); (d) MM96L treated with compound of example 67 (10 pg/mL). Figure 7. Oral Bioavailability. Time dependent plasma concentration of 30 compound of example 24 after oral (top) and intravenous (bottom) administration at 5 mg/kg to each of three Wistar rats.

WO 2005/051901 PCT/AU2004/001667 24 Detailed Description of the Invention 5 The compounds of the invention have been found to possess cytotoxic effects against cancer cells and are therefore useful in methods for the treatment of cancer in animals especially humans. As used herein the term 'cancer' is a general term intended to encompass the more than 100 conditions that are characterised by uncontrolled abnormal growth of cells. 10 Examples of cancer types that may be able to be treated by the compounds of the present invention include bone cancers including Ewing's sarcoma, osteosarcoma, chondrosarcoma and the like, brain and CNS tumours including acoustic neuroma, neuroblastomas and other brain tumours, spinal cord 15 tumours, breast cancers, colorectal cancers, endocrine cancers including adenocortical carcinoma, pancreatic cancer, pituitary cancer, thyroid cancer, parathyroid cancer, thymus cancer, multiple endocrine neoplasma, gastrointestinal cancers including stomach cancer, esophageal cancer, Small intestine cancer, Liver cancer, extra hepatic bile duct cancer, gastrointestinal 20 Carcinoid tumour, gall bladder cancer, genitourinary cancers including testicular cancer, penile cancer, prostrate cancer, gynaecological cancers including cervical cancer, ovarian cancer, vaginal cancer, uterus/endometrium cancer, vulva cancer, gestational trophoblastic cancer, fallopian tube cancer, uterine sarcoma, head and neck cancers including oral cavity cancer, lip cancer, 25 salivary gland cancer, larynx cancer, hypopharynx cancer, orthopharynx cancer, nasal cancer, paranasla cancer, nasopharynx caner, leukemias including childhood leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, acute promyelocytic leukemia, plasma cell leukemia, myelomas, haematological 30 disorders including myelodysplastic syndromes, myeloproliferative disorders, aplastic anemia, Fanconi anemia, Waldenstroms Macroglobulinemia, lung cancers including small cell lung cancer, non-small cell lung cancer, lymphomas including Hodgkinsons disease, non-Hodgkinsons's lymphoma, AIDS related Lymphoma, eye cancers including retinoblastoma, intraocular melanoma, skin WO 2005/051901 PCT/AU2004/001667 25 cancers including melanoma, non-melanoma skin cancer, merkel cell cancer, soft tissue sarcomas such as childhood soft tissue sarcoma, adult soft tissue sarcoma, Kaposi's sarcoma, urinary system cancers including kidney cancer, Wilms tumour, bladder cancer, urethral cancer, and transitional cell cancer. 5 Preferred cancers that may be treated by the compounds of the present invention are melanomas, skin, breast, prostrate and ovarian cancers. Various terms used throughout the specification have meanings that will be well 10 understood by a skilled addressee in the area. Nevertheless, for ease of reference, some of these terms will now be defined. The term "animal" as used throughout the specification is to be understood to mean ordinarily a mammal such as a human, sheep, horse, cattle, pig, dog, 15 cats, rat and mouse. For example, the animal may be a human subject suffering the effects of cancer. The term "alkyl" or "alk" as employed herein alone or as part of another group refers to a monovalent (e.g. -alkyl) or polyvalent (e.g. -alkyl-) saturated 20 hydrocarbon derived radical having the number of carbons specified or if no number is specified up to 30 carbons. The term includes straight or branched saturated hydrocarbon groups. The group preferably contains from 1 to 20 carbons, more preferably from I to 10 carbons, even more preferably 1 to 8 carbons in the normal chain. Examples of alkyl include but are not limited to 25 methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the various branched chain isomers thereof. The term "alkene" or "alkenyl" as used herein alone or as part of another group 30 refers to straight or branched unsaturated monovalent (e.g. -alkene) or polyvalent (-alkene-) hydrocarbon radical containing at least one carbon to carbon double bond. The group preferably contains from 2 to 20 carbons, preferably 2 to 12 carbons, most preferably 2 to 8 carbons in the normal chain. The group may include any number of double bonds in the normal chain and WO 2005/051901 PCT/AU2004/001667 26 the orientation about each double bond is independently E or Z. Examples of alkenyl include but are not limited to ethenyl (vinyl), 2-propenyl, 2-butenyl, 3 butenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 3 octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12 5 tetradecatrienyl, and the like. The term "alkyne" or "alkynyl" as used herein alone or as part of another group refers to a refers to straight, branched or cyclic unsaturated monovalent (e.g. alkyne) or polyvalent (e.g. -alkyne-) hydrocarbon radical containing at least one 10 carbon to carbon triple bond in the normal chain. The group preferably contains from 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain. Examples of alkynyl include but are not limited to ethynyl, 2-propynyl, 3-buyynyl, 2-butynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3 hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 2-octynyl, 3-octynyl, 4-octynyl, and 15 the like. The term "aryl" either alone or part of another group refers to monocyclic, bicyclic, tricyclic or polycyclic aromatic groups preferably containing from 6 to 20 carbons, more preferably from 6 to 14 carbons, even more preferably from 6 to 20 10 carbons. Examples of aryl include but are not limited to phenyl, 1-naphthyl, 2- naphthyl, anthracyl, phenanthryl, and benzonaphthenyl. These groups may optionally include one to three additional carbocyclic rings fused to the aromatic ring system 25 The term "cycloalkyl" alone or as part of another group indicates a saturated or partially unsaturated cyclic hydrocarbon preferably containing from I to 3 rings, including monocyclic alkyl, bicyclic alkyl (bicycloalkyl) and tricyclic alkyl (tricycloalkyl), and preferably containing a total of from 3 to 20 carbons forming the ring, preferably 3 to 10 carbons, forming the ring and which may be fused to 30 1 to 2 aromatic rings. Examples of cycloalkyl include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, adamantyl, and norbornyl WO 2005/051901 PCT/AU2004/001667 27 The term "heteroaryl" either alone or part of another group refers to groups containing an aromatic ring (preferably a 5 or 6 membered aromatic ring) having 1 or more heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, 5 sulfur, and nitrogen. Examples of heteroaryl include thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, 4H-quinolidine, isoquinoline, 10 quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, .beta.-carboline, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isoxazole, furazane, phenoxazine, 2-, 3-, or 4-pyridyl, 2-, 3-, 4-, 5-, or 8-quinolyl, 1-, 3-, 4-, or 5-isoquinolyl, 1-, 2-, or 3 indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, benzo[b]furanyl, 2- or 3-thienyl, or 15 the like. More preferred examples include 2- or 3-thienyl, 2-, 3-, or 4-pyridyl, 2 or 3-quinolyl, 1-isoquinolyl, 1- or 2-indolyl, 2-benzothiazoly, and the like. For ease of reference in the drawings heteroaryl is sometimes depicted with the following symbol. 20 This symbol is intended to be a shorthand notation for all heteroaryl groups whether monocyclic, bicyclic or polycyclic notwithstanding that a single ring is depicted in the shorthand notation. . 25 The term "heterocycloalkyl " as used alone or as part of another group refers to a saturated or partially unsaturated ring, preferably containing 5, 6, 7 or 8 ring atoms which includes at least one of nitrogen, sulfur or oxygen as a ring atom and which may further be fused to one or more aromatic or non-aromatic rings. Examples of heterocycloalkyl include 2- pyrolline, 3-pyrolline, pyrollidine, 1,3 30 dioxolane, 2-imidazoline, 2-pyrazoline, pyrazolidine. piperidine, morpholine. 1,4 dioxane, thiomorpholine, piperazine and indoline.

WO 2005/051901 PCT/AU2004/001667 28 The term "acyl" as used throughout the specification is to be understood to mean the groups alkyl-C(O)-, substituted alkyl-C(O)-, cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, heteroaryl-C(O)- and heterocycloalkyl 5 C(O)-. The term "alkoxy" as used throughout the specification is to be understood to mean the group "alkyl-O-". Preferred alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n 10 pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like. The term "amino" as used throughout the specification is to be understood to mean a nitrogen optionally mono-, di- or tri-substituted. 15 The terms "halo" or "halogen" as used throughout the specification is to be understood to mean fluoro, chloro, bromo or iodo. The term "optionally substituted" as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a 20 condensed polycyclic system), with one or more substituent groups. Preferably the substituent groups are one or more groups selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, 25 cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, 30 arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; WO 2005/051901 PCT/AU2004/001667 29 The term "protecting group" refers to a chemical group that exhibits the following characteristics: 1) reacts selectively with the desired functionality in good yield to give a protected substrate that is stable to the projected reactions for which protection is desired; 2) is selectively removable from the protected 5 substrate to yield the desired functionality; and 3) is removable in good yield by reagents compatible with the other functional group(s) present or generated in such projected reactions. Examples of suitable protecting groups can be found in Greene et al. (1991) Protective Groups in Organic Synthesis, 2nd Ed. (John Wiley & Sons, Inc., New York). Preferred amino protecting groups include, but 10 are not limited to, benzyloxycarbonyl (CBz), t-butyloxycarbonyl (Boc), t butyldimethylsilyl (TBDIMS), 9-fluorenylmethyloxycarbonyl (Fmoc), or suitable photolabile protecting groups such as 6-nitroveratryloxy carbonyl (Nvoc), nitropiperonyl, pyrenylmethoxycarbonyl, nitrobenzyl, dimethyl dimethoxybenzil, 5-bromo-7-nitroindolinyl, and the like. Preferred hydroxyl protecting groups 15 include Fmoc, benzyl, t-butyl, allyl, TBDIMS, photolabile protecting groups (such as nitroveratryl oxymethyl ether (Nvom)), Mom (methoxy methyl ether), and Mem (methoxy ethoxy methyl ether). Particularly preferred protecting groups include NPEOC (4-nitrophenethyloxycarbonyl) and NPEOM (4 nitrophenethyloxymethyloxycarbonyl). 20 The term "Selectivity Index" is used to describe the ratio of compound cytoxic activity, as measured by IC50 values, for normal cells over tumor cells. Unless otherwise specified, the Selectivity Index refers specifically to IC50 (NFF)/ IC5o (MM96L). IC5o is a measurement of the concentration of a compound needed to 25 reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. 30 As used throughout the specification the preferred number of carbon atoms will be represented by, for example, the phrase "Cx-Cy alkyl" which refers to an alkyl group as hereinbefore defined containing the specified number of carbon atoms. Similar terminology will apply for other variable.

WO 2005/051901 PCT/AU2004/001667 30 Pharmaceutically acceptable derivatives and solvates of the compounds of the invention are also contemplated herein. The term "pharmaceutically acceptable derivative" as used throughout the specification is to be understood to mean a compound that is a drug precursor, which, upon administration to a subject, 5 undergoes chemical conversion by metabolic or chemical processes to yield a compound of formula (1) or a salt and/or solvate thereof. The term is used interchangeably with the term 'prodrug'. The term "solvate" as used throughout the specification is to be understood to 10 mean a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" 15 encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H 2 0. The term "composition" as used throughout the specification is to be understood 20 to mean a product containing the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Log D 7

.

0 refers to the lipophilicty of the compounds of the invention and was 25 calculated at pH 7 (Log D 7

.

0 being the octanol/water partition coefficient) using the program PALLAS. The term "therapeutically effective amount" or "therapeutic amount" is an 30 amount sufficient to effect beneficial or desired clinical results. An effective amount can be administered in one or more administrations. An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state.

WO 2005/051901 PCT/AU2004/001667 31 Compound Design The compounds were designed on the basis that human histone deacetylases (HDACs) are known to regulate the equilibrium between acetylated and deacetylated nuclear proteins known as histones, and that this control in turn 5 influences the degree of interaction between histones and the DNA in which histones are normally wrapped. One role for histone deacetylases then is to increase the proportion of histones wrapped in DNA, and inhibitors of this enzyme can thus enhance the unwrapping. 10 The specific molecular interactons between DNA and histones are mediated through lysine side chains of histones. Histone lysines possess side chains consisting of a -(CH 2

)

4

-NH

2 terminus which when acetylated (-(CH 2

)

4 NHCOCH 3 ), inserts into the active site of HDAC enzymes and makes contact with a zinc ion. 15 The three dimensional structure of a bacterial HDAC enzyme analogue (HDLP) has been solved both as the native enzyme, and co-crystallized with the HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid (SAHA). HDLP shares -32% homology with HDACI and deactetylates histones in vitro. High 20 sequence homology is observed within the hydrophobic tubular catalytic active site, -11 A deep but narrowing to -4 A at the active site and terminating at a divalent zinc cation, activated water molecule, and histidine-aspartate charge relay system. Most of the residues in the HDLP structure that interact directly with trichlorstatin are highly conserved among all the HDACs, but there is less 25 conservation in adjoining residues, most notably on the enzyme surface which has a number of shallow pockets surrounding the active site channel: Docking of trapoxin B into the HDLP crystal structure using a combination of conformational searching (MACROMODEL) and a genetic docking algorithm 30 (GOLD) identified tight binding conformations in which the aliphatic side chain had inserted into the tubular pocket of the active site, with the Phe side chains in contact with the shallow pockets of the enzyme surface (Glenn et al., 2004). These aromatic groups represent important foliage on the cyclic tetrapeptide scaffold for tight enzyme binding, and similar groups are represented in related WO 2005/051901 PCT/AU2004/001667 32 naturally occurring cyclic tetrapeptides (Phe, Trp, Tyr). However, cyclic tetrapeptides offer limited scope for potential therapeutics due to their difficulty of synthesis, problematic stability, and conformational homogeneity. It was generally conceived that active compounds could be developed by mimicking 5 the key enzyme binding regions of Trapoxin B, which would include a zinc chelator tethered to a branched capping group capable of reproducing the approximate positions and orientations of the Phe side chains, on a much simplified template. It was envisaged that a tripeptide incorporating similar surface binding groups to those found in the potent naturally occurring cyclic 10 tetrapeptide inhibitors (hydrophobic, aromatic, basic) would be able to span the surface binding domain of Trapoxin B, while a hydrophobic tether terminating at a hydroxamic acid would ensure firm zinc binding in the catalytic core. Analysis of the problem led to the conclusion that amino acid like frameworks 15 derived from either cysteine or alpha 7-substituted 2-amino-heptanoate have the potential to meet the above requirements as they provide the appropriate functionality, chirality and orientation to mimic the cyclic peptide, trapoxin B. Synthetic studies in this area were therefore directed towards the use of 20 cysteine and 7-substituted 2-amino-heptanoate like frameworks as building blocks from which improved compounds could be developed. These studies led to the development of the compounds of the invention. Thus, the present invention provides a compound having the formula (I), or a 25 pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

R

6 o R7-,X',N Z-R--M (1) 30 wherein WO 2005/051901 PCT/AU2004/001667 33 Z is S or CH 2 ; R1 is a linking moiety; 5 M is a zinc binding moiety containing at least one heteroatom;

R

6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; 10 X is selected from the group consisting of: 0. S 0 -CH2- -C- -C- and -- S 0 15 Y is selected from the group consisting: of -NR 4

R

5 , -OR 4 , -SR 4 , -CH 2

R

4 ,

CHR

4

R

5 , C(R4) 2

R

5 , PHR 4 and PR 4

R

5 , wherein R 4 is a group of formula: 20 O H (R8)p-(R9)q C-N r(R10), wherein R 8 , R 9 and R 10 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, 25 optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; WO 2005/051901 PCT/AU2004/001667 34 p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1;

R

5 is H or a group of formula: 5 O0 H II (R11)t-(R12)u C- N v(R13), wherein R 11 , R 12 and R 113 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted 10 alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of 15 t, u and w is 1;

R

7 is a group of formula: (Ri 6)z-(Ri 5)y-(R1 4)x 20 wherein R 14 , R 15 and R 1 6 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally 25 substituted heterocycloalkyl, x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1. 30 In one particular embodiment of the invention the compound having the formula (I) is based on cysteine. Accordingly, the embodiment of the invention provides WO 2005/051901 PCT/AU2004/001667 35 a compound of formula (Ila), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

R

6 o R7-, X'-N S- R 1 - M 5 (Ila) wherein R 1 , Rr, R 7 , M, X and Y are as defined above for the compound of formula (I). In another embodiment of the invention the compound having the formula (1) is 10 based on a 7-substituted 2-amino-heptanoates. Accordingly, the embodiment of the invention provides a compound of formula (Ilb), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

R

6 o R1-M (Ilb) 15 wherein R 1 , R 6 , R 7 , M, X and Y are as defined above for the compound of formula (I). As would be clear to a skilled addressee any number of suitable moieties can be used as the linking moiety of the compounds of the invention. It is typical, 20 however, that the linking moiety is a hydrocarbyl moiety that is unbranched. Moieties of this type are the simplest to produce and are found to not interfere with the activity of the remainder of the compound. It is preferred that the linker has between 1 and 9 atoms in the normal chain, preferably between 1 and 4 atoms in the normal chain. 25 In addition the zinc binding moiety can be chosen so that it is any suitable moiety that will bind to zinc. There are a number of suitable zinc binding WO 2005/051901 PCT/AU2004/001667 36 moieties well known in the art. Examples of well known zinc binding moieties include sulfur donors (such as HS-R, wherein R is defined above), amine containing compounds (primary, secondary, tertiary amines), heterocyclic amines, carboxylates, amino acids, thiolates, dithiocarbamates, 5 phosphorodidithiolates and the like. Some examples of suitable moieties within these subsets are as follows: Sulfur donors (thioproline, penicillamine, cysteine, 2-mercaptoethylamine, glutathione, methionine, thiosulfate, N-acetylcysteine, penicillaminedisulfide, 10 thiomalate, and 2,3-dimercaptosuccinate Aliphatic amines (histamine, trien, Me4en) Heterocyclic amines (pipicolate, nicotinate, picolinate, 8-hydroxyquinoline, 15 bicinchoninate, bipy, phendisulfonate) Carboxylates (acetate, propionate, tartrate, succinate, malate, gluconate, betahydroxybutyrate, lactate, salicylate, citrate, ascorbate, oxalate, EDTA) 20 Amino acids (gly, arg, asn, glu, asp, glygly, glyglygly, glyglyhis, pro, 2,3 diarninopropionate, 2-amino-2-deoxygluconate, his) It is preferred that the zinc binding ligand is a hydroxamic acid derivative. 25 As with all chemical families there are a number of preferred embodiments within the scope of the general formula. It is preferred, for example that the group Y is a group of formula -NR 4

R

5 . 30 It is particularly preferred that the zinc binding moiety containing a heteroatom is a hydroxamic acid derivative, preferably a group of formula -C(O)-NR 2

-OR

3 where R 2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group and R 3 is H, optionally substituted alkyl, optionally substituted alkenyl, WO 2005/051901 PCT/AU2004/001667 37 optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group; Accordingly in a preferred embodiment the present invention provides a 5 compound having the formula (Ill), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof: 1 6 0

R

7 N NIR5 R 4 1 / Ri-C(O)-N\ R2 10 (111) wherein Z is S or CH 2 ; 15

R

1 is optionally substituted C1C4 alkyl, optionally substituted C-C4 alkenyl or optionally substituted C1C4 alkynyl;

R

2 is H, optionally substituted alkyl, optionally substituted alkenyl, 20 optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group;

R

3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or an oxygen 25 protecting group;

R

4 is a group of formula: WO 2005/051901 PCT/AU2004/001667 38 O H

(R

8 )p- (R 9 )q C-N r (R 1 0) wherein R 8 , R 9 and R 1 0 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, 5 optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; p, q, r and s are each independently 0 or 1, provided that at least one of 10 p, q or s is 1;

R

5 is H or a group of formula: O H (RI )t- (R1 2)u C- N(R) 15 wherein R 11 , R 12 and R 113 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally 20 substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1. 25 R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; X is selected from the group consisting of 30 WO 2005/051901 PCT/AU2004/001667 39 O S 0 -CH2-C- -C- and -S

R

7 is a group of formula: 5 (R16)r(R15)y-(R14)x wherein R 1 4 , R 1 5 and R 16 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally 10 substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl; x, y and z are independently 0 and I with the proviso that at least one of x, y and z is 1. 15 As stated previously there are a number of compounds within the scope of the general structural formula that are preferred. There are therefore a number of preferred variables for each of the substituents in the general formula. For example it is preferred that R 1 is optionally substituted C 1

-C

4 alkyl, more 20 preferably optionally substituted C2-C3 alkyl, even more preferably optionally substituted C3 alkyl, most preferably propyl. It is preferred that R 2 is either H, optionally substituted C1-C4 alkyl or a nitrogen protecting group, more preferably H or a nitrogen protecting group, most 25 preferably H. It is preferred that R 3 is either H, optionally substituted C-C 4 alkyl or an oxygen protecting group, more preferably H or an oxygen protecting group, most preferably H. 30 WO 2005/051901 PCT/AU2004/001667 40 In a most preferred embodiment, the compounds are of formula (Illa) and (1lb).

R

6 o

R

7 X NN R 5 R4 S NH-OH 0 (ilila) 5

R

6 o R7, N5 X N R4 NH-OH 0 (Illb) 10 In the compounds of the invention it is particularly preferred that X is a carbonyl group. It is preferred that R 5 is H. 15 It is preferred that R3 is either H or a nitrogen protecting group, most preferably H. In one preferred embodiment the group R4 is of the formula O H 20

-R

8

-R

9

-C-N-R

1 0 wherein R 8 , R 9 and R 10 are as defined above.

WO 2005/051901 PCT/AU2004/001667 41 In this embodiment it is particularly preferred that R 4 is of the formula: O H -(optionally substituted alkyl)- (optionally substituted aryl)-C-N- (optionally substituted aryl) 5 In the most preferred form of this embodiment R 4 is a group of the formula. (R)n (R)m I I - I -CH 2

C

wherein each R is independently selected from the group consisting of alkyl, 10 alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, 15 nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, 20 carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; n is 0-4, and 25 m is 0-5. In an another preferred embodiment of the invention R 4 is selected from the group consisting of: optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted 30 cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted WO 2005/051901 PCT/AU2004/001667 42 heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl alkenyl, optionally substituted heteroaryl alkenyl, optionally substituted cycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted aryl alkynyl; 5 optionally substituted heteroaryl alkynyl optionally substituted cycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl. In this embodiment it is particularly preferred that R 4 is selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted 10 heteroaryl, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkyl alkyl, optionally substituted alkyl aryl, optionally substituted alkyl heteroaryl, optionally substituted alkyl heterocycloalkyl. 15 In a most preferred embodiment of the invention R 4 has one of the following formulae. (R), (R)m (R)m F-O +alkyl6 alkyl4 (R)m (R)m (R)m e + alkenyl - alkenyl H 20 wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, 25 haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, WO 2005/051901 PCT/AU2004/001667 43 arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; 5 and each m is from 0-5. Preferred values of R as substituents on R 4 are dialkyl amino, acyl, aryl, carboalkoxy, benzyl, cycloalkyl, heteroaryl, hydroxy, halo and cyano. 10 Particularly preferred values of R 4 are dimethyl amino, diethyl amino, bromo, phenyl and benzyl. In the compounds of the invention it is preferred that R 7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, 15 optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heteroaryl alkyl, optionally substituted cycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted aryl alkenyl, optionally substituted 20 hetero alkenyl, optionally substituted cycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted aryl alkynyl, optionally substituted heteroaryl alkynyl, optionally substituted cycloalkyl alkynyl, optionally substituted and heterocycloalkyl alkynyl. 25 It is even more preferred that R 7 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted alkenyl, optionally substituted aryl alkenyl. 30 It is most preferred that R 7 has one of the following formula: WO 2005/051901 PCT/AU2004/001667 44 (R)p (R)p (R)p alkyl+ alkyl (R~p(R)p (R)p ~~alkenyl- 4alkenyl ~Het akn1-. Het akn1. wherein each R is independently related from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, 5 haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, 10 dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylarnino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate 15 and phosphate; and each p is from 0-5. Particularly preferred values of R as a substituent on an R 7 group are 20 dialkylamino, alkoxy, halo, aryl, alkyl, hydroxy, nitro and arylamino. Preferred compounds of the invention include those listed in tables I to 9 in the examples. 25 Synthesis of the compounds of the invention Compounds of formula (1) may be generated in a number of ways depending on the synthetic strategy adopted and the available starting materials. As would be WO 2005/051901 PCT/AU2004/001667 45 clear to a skilled addressee the exact method utilised will depend on the available starting materials. Isolation and purification of the compounds and intermediates described herein 5 can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallisation, column chromatography, thin-layer chromatography, thick-layer (preparative) chromatography, distillation, HPLC or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had 10 by reference to the examples provided herein. However, other equivalent separation or isolation procedures can also be used. Preparation of compounds of formula (//a) 15 The applicants have identified an efficient methodology for producing the compounds of formula (Ila) that progresses through an advanced intermediate of formula (3): 0 PgiHN OPg 2 S- R 1 - C(O)OPg 3 20 (3) Wherein Pg1 is a protecting group for nitrogen and Pg 2 and Pg 3 are protecting groups for oxygen and R 1 is as previously defined. The protecting groups in 25 formula (3) may be any suitable groups that are suitably adapted for the remaining steps of the process. It is important, however that the two carboxylic acid protecting groups can be differentially de-protected so that the two groups can be separately functionalised. A preferred form of the compound of formula (3) can be made utilising the reaction sequence outlined in scheme 1. 30 Modifications to this general scheme can be made to produce compounds of formula (3) with other protecting groups and/or general structures. The extent WO 2005/051901 PCT/AU2004/001667 46 of the modifications and the way in which could be done are well within the ambit of a skilled addressee in the art. Cl-R 1 -C-Cl (a) Cl-R 1 -C-0-tBu II II 0 O (4) (5) (b) 0

H

2 NOH :4 (C)

I-R

1 -C--tBu S-RI-C-0--tBu 11 (7) (6) (d) o 0 FmocHN - O (FmocHN

S-R

1 -C-0-tBu S-R 1 -C-0-tBu || II o 0 5 (8) (9) (a) tBuOH, Pyridine (b) Nal, THF (c) Cys, NaOH, MeOH (d) Fmoc-OSu, NaHCO3, THF, Water (e) allyl bromide, DMF, K 2 CO3 10 Scheme I Referring to scheme I carboxylic acid chloride (4) with the desired R 1 group is converted to the protected form by reaction with tertiary butanol in pyridine to WO 2005/051901 PCT/AU2004/001667 47 produce the t-butyl protected form (5). The choice of protecting group will vary depending on a number of factors including the identity of the further protecting group chosen. The choice of a suitable protecting group will typically not cause difficulty for a skilled addressee and can vary greatly with the preferred group 5 being t-butyl. The protected carboxylic acid (5) is then reacted with sodium iodide to produce the iodinated derivative (6). This is then reacted with an appropriate thio derivative such as cysteine to produce intermediate (7). This compound is then 10 protected at both the C and N termini. Accordingly it is preferred that the compound is reacted with a nitrogen protecting group such as Fmoc to produce the N-protected compound (8) which is then in turn reacted with allyl bromide to produce the final differentially protected compound (9). In the preferred embodiment of the invention R 1 is propyl and the production of the preferred 15 compounds follows an analogous procedure as that shown in scheme 1 with the starting compound (4) being the acid chloride of 4-chlorobutyric acid. In order to vary the group R 1 in the final compounds of the invention all that is required is that the starting material (4) contain the suitable R 1 . In general a skilled worker in the field will easily be able to produce a wide range of compounds of general 20 formula (4) with different values of R 1 from commercially available starting materials. In addition whilst in the reaction scheme shown above the iodinated compound (6) is reacted with naturally occurring cysteine it could equally be reacted with the unnatural isomer or even a mixture of isomers. 25 The compounds of formula (9) are then converted into compounds of the invention utilising the general procedure given in scheme 2.

WO 2005/051901 PCT/AU2004/001667 48 O 0 FmocHN O FmocHN (a)

S-R

1 -C-0-tBu S-R-C 2 H 0 (9) (10) I (b) O 0 FmocHN FmocHN OH (c) O H O H SR1-- S-RI-C-N-0--(o S- Ri-C-N---O (12) (d) 0 0 FmocHN

NR

4

R

5 H 2 N NR 4

R

5 O H 0*, H S-R1-C-N-0-0

S-R

1 -C-N-0--Q (13) (14) 1(f) H H 0 10

R

7 X- NR 4

R

5 (g) N NR 4

R

5 HOH I S-RI-C-N-O-O

S-R

1 -C-N-OH (15) (16) (a) TFA, (b) HATU, DIPEA, 2 Chlorotrityl resin, DMF, (c) Pd(PPh 3

)

4 , DMBA, (d)

HNR

4

R

5 , HBTU, DIPEA, DMF, (e) Piperidine, (f) R 7 X-L, HBTU, DIPEA, DMF, 5 (g) TFA. Scheme 2 Thus the compound of formula (9) is de-protected by reaction with TFA to differentially remove the t-butyl protecting group and form compound (10). This WO 2005/051901 PCT/AU2004/001667 49 de-protected compound is then reacted with an appropriately modified resin to immobilise the compound on the resin and form immobilised compound (11). The immobilised compound is then treated with palladium to remove the allyl protecting group to form immobilised acid (12). Reaction of acid (12) with an 5 appropriately substituted nucleophillic compound such as amine of formula

(HNR

4

R

5 ) produces advanced compound (13). This is then reacted with piperidine to remove the Fmoc protecting group to produce the free amine (14). Reaction of amine (14) with a group of formula R 7 XL where L is a leaving group then produces compound (15). The compound can then be removed from the 10 solid support by reaction with TFA under appropriate conditions to form the compound (16) of the invention. Preparation of compounds of formula (fib) 15 Using a similar methodology to that described for compounds of formula (Ila), synthesis of the compounds of formula (Ilb) progresses through an advanced intermediate of formula (17): 0 PgjHN OPg2

R

1 -C(O)OPg 3 20 (17) Again, Pg1 is a protecting group for nitrogen and Pg 2 and Pg 3 are protecting groups for oxygen and R 1 is as previously defined. The protecting groups in 25 formula (17) may be any suitable groups that are suitably adapted for the remaining steps of the process. A preferred form of the compound of formula (17) can be made utilising the reaction sequence outlined in scheme 3. Modifications to this general scheme can be made to produce compounds of formula (17) with other protecting groups and/or general structures. The extent 30 of the modifications and the way in which could be done are well within the ambit of a skilled addressee in the art.

WO 2005/051901 PCT/AU2004/001667 50 H 0H O (a), (b), (c) I N -0 N N OEt N OH 0 OEt

R

1 OtBu (18) (19) (d), (e) H 0 0 OH FmocHN OH 0

R

1 O'Bu R 1 OtBu O O (20) (f) FmocHN O

R

1 OtBu (21) (a) 1. NaH, DMF; 2. I-Rr-CO 2 tBu; (b) LiCI-H 2 0, DMSO, 160 'C; (c) LiOH, H 2 0:EtOH; (d) 5 Acylase I (aspergillus melleus), CoC1 2 , phosphate buffer pH 7.2; (e) Fmoc-OSu, NaHCO 3

THF:H

2 0; (f) ally] bromide, NaHCO 3 , DMF. Scheme 3 WO 2005/051901 PCT/AU2004/001667 51 Referring to scheme 3, malonate diester (18) is alkylated with the desired R 1 caboxylate having an appropriate leaving group (e.g. iodide) and then decarboxylated and saponified to produce the acid (19). Enzymatic resolution followed by protection with a nitrogen protecting group such as Fmoc produces 5 the N-protected (S)-enantiomer (20) which is then in turn reacted with allyl bromide to produce the final differentially protected intermediate (21). In a preferred embodiment of the invention R 1 is propyl and the production of the preferred compounds follows an analogous procedure as that shown in 10 scheme 3 with the malonate diester (18) being reacted with 6-iodohexanoic acid tert-butyl ester. In order to vary the group R 1 in the final compounds of the invention all that is required is that the iodo acid tert-butyl ester contains the suitable R 1 . In general a skilled worker in the field will easily be able to produce a wide range of suitable compounds with different values of R, from 15 commercially available starting materials. In addition whilst in the reaction scheme shown above the racemate (19) is resolved by enzymatic resolution, it will be appreciated that the chiral resolution may be omitted and the acetate group removed from the N-terminus in the racemic mixture and the free amine then protected with a suitable N-protecting group (in this case Fmoc) to produce 20 a racemic mixture of compound (20) which can then be carried through the remainder of the steps. The compounds of formula (21) are then converted into the compounds of the invention utilising the general procedure given in scheme 4. 25 WO 2005/051901 PCT/AU2004/001667 52 O 0 FmocHN O FmocHN O (a)

R

1 -C-O-tBu -R 1

-CO

2 H I I 0 (21) (22) I (b) O 0 FmocHN FmocHN O - OH (c) O H 0 OH R - -N--R-C-N-0-0 '\R-C-N-O-Q (24) (23) (d) 0 0 FmocHN NR 4

R

5 H 2 N NR 4

R

5 O H (e) -~ OH RI--N-0--Q

R

1 --- N-0--O (25) (26) 1(f) H 0H O

R

7 X-N NR 4

R

5 (g) R7XNR 4

R

5 O H

R

1 -C-N-0--o

R

1 -C-N-OH (27) (28) (a) TFA, (b) HATU, DIPEA, 2 Chlorotrityl resin, DMF, (c) Pd(PPh 3

)

4 , DMBA, (d)

HNR

4

R

5 , HBTU, DIPEA, DMF, (e) Piperidine, (f) R 7 X-L, HBTU, DIPEA, DMF, 5 (g) TFA. Scheme 4 It will be appreciated the steps of scheme 4 may be carried out in the same manner as the steps of scheme 2.

WO 2005/051901 PCT/AU2004/001667 53 Use of compounds of the invention for the treatment of cancer The present invention also provides a method for the treatment of cancer in an 5 animal, the method including the step of administering to the animal in need of such treatment an effective amount of a compound having the formula (I), as hereinbefore described, or a pharmaceutically acceptable derivative, salt, racemate, or isomer thereof. 10 The compounds of this invention may be administered in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions for injectable administration, and the like, or incorporated into shaped articles. Typical adjuvants which may be incorporated into tablets, capsules and the like are a binder such as acacia, corn starch or gelatin, and 15 excipient such as microcrystalline cellulose, a disintegrating agent like corn starch or alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose or lactose, or a flavoring agent. When a dosage form is a capsule, in addition to the above materials it may also contain a liquid carrier such as water, saline, fatty oil. Other materials of various types may be used as 20 coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants 25 and the like can be incorporated according to accepted pharmaceutical practice. While the preferred route of administration is oral, other methods of administration are also anticipated such as intravenously (bolus and/or infusion), subcutaneously, intramuscularly, transdermally, colonically, rectally, 30 nasally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, injectable formulations and topical formulations such as ointments, drops and dermal patches. The compounds of this invention could be incorporated into shaped articles such as implants which may employ inert materials such as WO 2005/051901 PCT/AU2004/001667 54 biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available. The compounds of this invention may also be administered in the form of 5 liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines. Formulations of the compounds of this invention are prepared for storage or 10 administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilisers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, 15 Mack Publishing Co., (A. R. Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and may include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, 20 gelatin, or immunoglobulins, hydrophilic polymers such as polyvinalpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions 25 such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol. Animals in need of treatment using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method 30 of administration will vary from animal to animal and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognise.

WO 2005/051901 PCT/AU2004/001667 55 Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The 5 range of therapeutically effective dosages will naturally be influenced by the route of administration, the therapeutic objectives, and the condition of the patient. It may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to 10 achieve the desired result, will be within the knowledge of one skilled in the art. For example it is typical that for any compound used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from cell culture assays. Then, the dosage can be formulated for use in animal models so as to achieve a circulating concentration range that includes the IC 5 o 15 as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the PK activity). Such information can then be used to more accurately determine useful doses in humans. Toxicity and therapeutic efficacy of the compounds described herein can be 20 determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 5 0 (the dose lethal to 50% of the population) and the EDo (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 5 0 and ED 50 . 25 Compounds that exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity. The dosage may vary within this range 30 depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition- (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

WO 2005/051901 PCT/AU2004/001667 56 Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved. Generally a dosage of as little as about 1-2 milligram (mg) per kilogram (kg) of 5 body weight is suitable, but preferably as little as 1 mg/kg and up to about 100 mg/kg may be used. Preferably, a dosage from 2 mg/kg to about 40 mg/kg is used. Most preferably, the dose is between 4 mg/kg to about 8 mg/kg. Any range of doses can be used. Generally, a compound, salt thereof, prodrug thereof, or combination of the present invention can be administered on a daily 10 basis one or more times a day, or one to four times a week, either in a single dose or separate doses during the day. Twice-weekly dosing over a period of at least several weeks is preferred, and often dosing will be continued over extended periods of time and possibly for the lifetime of the patient. However, the dosage and the dosage regimen will vary depending on the ability of the 15 patient to sustain the desired and effective plasma levels of the compounds of the present invention, or salt or prodrug thereof, in the blood. In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or 20 diagnostic agents. In certain preferred embodiments, the compounds of this invention may be co-administered along with other compounds typically prescribed for these conditions according to generally accepted medical practice. For example, compounds of this invention may be used in combination with DNA methyltransferase inhibitors (as described in Herman JG 25 and Baylin SB (2003) NEJM 349, 2042-2054). Such inhibitors may include but are not limited to 5-azacytidine, deoxy-5-azacytidine, or zebularine. The compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting 30 moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.

WO 2005/051901 PCT/AU2004/001667 57 Furthermore, the compounds of this invention may be coupled to a biodegradable polymer for achieving controlled release of a drug. Examples of such polymers include polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, 5 polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like. 10 Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilise the compounds of the present invention and practice the claimed methods. 15 The following abbreviations are used in the examples and elsewhere throughout the specification: Ac = acetyl; DCM = Dichloromethane; DIPEA = diisopropylethylamine; 20 DMAP = 4-(Dimethylamino)pyridine; DMBA = 1,3-Dimethylbarbituric acid; DMF = dimethylformamide; EtOAc = Ethyl acetate; Fmoc-OSu = 9-Fluorenylmethyloxycarbonyl-N-hydroxysuccinimide; 25 HATU=O-(7-azabenzotriazol-1 -yl)-1,1,3,3tetramethyluroniumhexafluoro phosphate; HBTU =[(benzotriazolyl)oxy]-,N',N', N' tatramethyluroniumhexafluorophosphate; rpHPLC = reverse phase high performance liquid chromatography; 30 LRMS = Low resolution mass spectroscopy; TFA = trifluoroacetic acid; THF = tetrahydrofuran.

WO 2005/051901 PCT/AU2004/001667 58 The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure. 5 Examples of Preferred Embodiments of the Invention General methods 1 H NMR spectra were recorded on either a Bruker ARX 500 MHz or a Varian 300 MHz NMR spectrometer. Semi preparative scale rpHPLC separations were 10 performed on a Phenomenex Luna 54 C18(2) 250 x 21 mm column run at 20 mL/minute using gradient mixtures of water/0.1% TFA (A) and water (10%)/acetonitrile (90%)/0.1% TFA (B), and product fractions were always lyophilized to dryness. Preparative scale rpHPLC separations were performed on a Vydac 218TP101550 50 x 250 mm column run at 70 mL/minute using 15 gradient mixtures of A and B. Accurate mass determinations were performed on an API QSTAR mass spectrometer using electron impact ionization. Water octanol partition coefficients (Log D) were calculated using PALLAS prolog D 2.1. Molecular modeling was performed on an SGI Octane R12000, with minimization calculation performed with the cff9l force field using the Discover 20 Module within Insight 11. Example 1 Coupling of acid to resin (general method) Commercially available N-Fmoc hydroxylamine 2-chlorotrityl resin (0.77 mmol/g, 25 10 g, 7.7 mmol) was shaken gently with 1:1 piperidine:DMF (30 mL) over night, and then flow washed with DMF for 1 minute. In a separate flask, HATU (3.0 g, 7.8 mmol) was added to a solution of the acid (7.8 mmol) and DIPEA (5.3 mL, 31.2 mmol) dissolved in DMF (10 mL), and the resulting solution stirred gently for 5 minutes. The HATU activated acid was then added in one portion to the 30 deprotected resin, and the resin was shaken gently for 1 hour. After washing the resin well with DMF, the resin loading was determined. The unreacted resin was then acylated by addition of a solution of acetic anhydride (842 mg, 7.8 mmol) and DIPEA (5.3 mL, 31.2 mmol) in DMF (20mL) with shaking for 2 minutes, followed by thorough washing with DMF.

WO 2005/051901 PCT/AU2004/001667 59 Example 2 Coupling of Acid moiety with functional group to add NR 4

R

5 group (general method) 5 The resin (0.45 mmol/g, 200mg, 0.09 mmol) was shaken in DMF (1 mL) for 10 minutes, and then DIPEA (122 piL, 0.72 mmol) and 0.5 M HBTU in DMF (360 [pL, 0.18 mmol) were introduced and shaking continued for a further 5 minutes. The amine (0.25 mmol) was then added, and shaking continued for a further 1 hour. After washing the resin well with DMF, cleavage of a small portion of 10 resin and analysis by mass spectroscopy generally indicates 60-85% conversion to the amide. Example 3 Coupling of amine moiety with functional group to add R 7 X group (general 15 method) The resin was shaken in DMF (1 mL) for 10 minutes, the DMF removed, and then 1:1 piperidine:DMF (1 mL) added. After shaking for 5 minutes the piperidine:DMF was removed, and the resin washed well with DMF. This procedure was repeated two more times. In a separate flask 0.5 M HBTU (180 20 pLL, 90 [pmol) in DMF was added to a solution of the desired acid (90 pM) and DIPEA (76 [pL, 450 [pmol) in DMF (1 mL), and the resulting solution stirred for 5 minutes before being added in one portion to the resin. The resin was shaken for 1 hour, and then washed well with DMF. Cleavage of a small portion of resin and analysis by mass spectroscopy generally indicates 100% conversion to the 25 amide. Example 4 Cleavage of immobilised compound from resin (general method) The resin was washed well with DCM, and then drained. TFA:water (99:1, 1 mL) 30 was added, and the resin shaken for 20 minutes. The TFA was collected, and the resin washed with a further 1 mL of TFA. The TFA was removed by distillation. Purification was performed by rpHPLC, and hydroxamates confirmed to be greater than 95% pure by analytical rpHPLC and 1 H NMR spectroscopy.

WO 2005/051901 PCT/AU2004/001667 60 Production of a preferred Intermediates Example 5 4-Chloro-butyric acid tert-butyl ester. 5 4-Chlorobutyryl chloride (16.6 mL, 147 mmol) was added drop wise to a cooled (0 0C) solution of DMAP (10 mg) in equal portions of tert-butanol (50 mL) and pyridine (50 mL). After complete addition of the acid chloride, the resulting suspension was stirred for 1 hour, and then solvent removed under reduced pressure. The residue was dissolved in EtOAc (500 mL), and washed 10 successively with saturated NaHCO 3 and NaCI solutions. The organic layer was dried over magnesium sulfate, and solvent removed to provide the tert-butyl ester as a clear oil (22.3 g, 85%). 1 H NMR (CDC13, 300MHz): 3.58 (t (6.4 Hz), 2H); 2.40 (t (7.3 Hz), 2H); 2.06 (m, 2H); 1.45 ppm (s, 9H). 13C NMR (CDCl 3 , 75MHz): 172.5, 81.1, 44.8, 33.1, 28.6, 28.4 ppm. 15 Example 6 4-lodo-butyric acid tert-butyl ester Sodium iodide (70.0 g, 467 mmol) was added to tert-butyl ester of example 5 (22.0 g, 124 mmol) dissolved in THF (300 mL), and the resulting yellow 20 suspension was refluxed overnight. The solvent was removed under reduced pressure, and the residue dissolved in EtOAc (200 mL). After washing successively with water and saturated NaCl solution the organic phase was dried over magnesium sulfate, and solvent removed to provide the title iodide as a yellow oil (31.4 g, 94%). 1 H NMR (CDC13, 300MHz): 3.23 (t (6.7 Hz), 2H); 2.34 25 (t (7.3 Hz), 2H); 2.07 (m, 2H); 1.40 ppm (s, 9H). 13C NMR (CDC13, 75MHz): 173.2, 81.0, 44.6, 35.1, 28.9, 6.0 ppm. Example 7 4-((2S)-Amino-2-carboxy-ethylsulfanyl)-butyric acid tert-butyl ester: 30 A suspension of cysteine (6.6 g, 55.5 mmol) in methanol (50 mL) was cooled to 00C and degassed under a stream of argon for 5 minutes. On addition of 2M sodium hydroxide solution (55.5 mL, 111 mmol) the cysteine dissolved, and tert butyl ester of example 6 (15.0 g, 55.5 mmol) was added immediately in one portion. Stirring was continued for a further 5 minutes, before adjustment of the WO 2005/051901 PCT/AU2004/001667 61 pH to -8 with 2 M HCL. The solvent was removed under reduced pressure, and the residue desalted by rpHPLC to provide the title amino acid as a white solid (14.2 g, 97%). 'H NMR (d 6 -DMSO, 300MHz): 3.4 to 3.1 (br s, water); 2.97 (dd (3.8, 14.3 Hz), 1H); 2.70 (dd (8.7, 14.2 Hz), IH); 2.51 (t (7.4 Hz), 2H); 2.29 (t 5 (7.2 Hz), 2H); 1.72 (m, 2H); 1.38 ppm (s, 9H). 13C NMR (dB-DMSO, 75MHz): 175.2, 172.6, 80.2, 53.9, 34.0, 33.2, 30.6, 28.1, 24.7 ppm. Example 8 4-[(2S)-Carboxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethylsulfanyl] 10 butyric acid tert-butyl ester : NaHCO 3 (14 g, 170 mmol) and Fmoc-OSu (18.7 g, 55.5 mmol) were added to a solution of amino acid of example 7 (14.0 g, 53.0 mmol) dissolved in 1:1 THF water (300mL), and the resulting solution stirred for 2 hours. The solvent was removed under reduced pressure, and the residue suspended in EtOAc (300 15 mL), and washed successively with water, 1 M HCI, saturated NaHCO 3 solution and brine. The organic layer was dried over magnesium sulfate, and solvent removed under reduced pressure to yield a yellow oil which was purified by rpHPLC to provide the title acid as a white solid (19.7 g, 76%). 1 H NMR (d 6 DMSO, 300MHz): 7.90 (d (7.5 Hz), 2H); 7.73 (d (7.71 Hz), 2H); 7.42 (t (7.2 Hz), 20 2H); 7.32 (t (6.6 Hz), 2H); 4.65 (d (5.3 Hz), 2H); 4.30 (m, 2H); 2.91 (dd (3.7, 14.2 Hz), 1H); 2.76 (dd (8.6, 14.2 Hz), 1H); 2.51 (t (7.3 Hz), 2H); 2.26 (t (7.2 Hz), 2H); 1.72 (m, 2H); 1.39 ppm (s, 9H). "C NMR (d 6 -DMSO, 75MHz): 174.6, 172.1, 156.2, 144.2, 144.1, 128.0, 127.4, 125.6, 120.5, 79.6, 60.5, 54.5, 46.8, 34.0, 33.2, 30.8, 28.1, 24.8 ppm. 25 Example 9 4-[(2S)-Allyloxycarbonyl-2-(9H-fluoren-9-ylmethoxycarbonylamino) ethylsulfanyl]-butyric acid tert-butyl ester: Allyl bromide (6.23 g, 51.5 mmol) was added in one portion to a suspension of 30 K 2

CO

3 (27 g, 200 mmol) and compound of example 8 (25.0 g, 51.5 mmol) in DMF (200 mL). The resulting solution stirred for 10 minutes, and then the solvent was removed under reduced pressure. The resulting residue was dissolved in EtOAc (500 mL) and washed successively with water, 1 M HCI, saturated NaHCO 3 solution, and brine. The organic layer was dried over WO 2005/051901 PCT/AU2004/001667 62 magnesium sulfate, and solvent removed under reduced pressure to provide the title allyl ester as a yellow oil (25.0g, 92%). 'H NMR (d 6 -DMSO, 300MHz): 7.89 (d (7.60 Hz), 2H); 7.72 (d (7.71 Hz), 2H); 7.41 (t (7.1 Hz), 2H); 7.32 (t (7.3 Hz), 2H); 5.88 (m, 1H); 5.31 (d (16.7 Hz), IH); 5.20 (d (11.7 Hz), IH); 4.59 (d 5 (5.3 Hz), 2H); 4.25 (m, 4H); 2.88 (dd (3.8, 14.1 Hz), 1H); 2.77 (m, 1H); 2.53 (t (7.3 Hz), 2H); 2.27 (t (7.3 Hz), 2H); 1.72 (m, 2H); 1.38 ppm (s, 9H). 13C NMR (d 6 -DMSO, 75MHz): 172.1, 170.9. 156.3, 144.1, 141.1, 132.6, 128.0, 127.4, 125.6, 120.5, 118.1, 80.0, 66.2, 60.1, 54.5, 47.0, 34.0, 32.7, 31.0, 28.1, 24.9 ppm. 10 Example 10 4-[2-Al lyloxycarbonyl-2-(9H -fl uoren -9-yl methoxycarbonylami no) ethylsulfanyl]-butyric acid : The ester of example 9 (25.0 g, 47.5 mmol) was stirred in 99:1 TFA:water (50 15 mL) for 2 hours. The solvent was removed under reduced pressure, and the residue purified by rpHPLC to provide the title acid as a white solid (19.5 g, 88%). 'H NMR (de-DMSO, 300MHz): 7.89 (d (7.1 Hz), 2H); 7.72 (d (7.1 Hz), 2H); 7.42 (t (7.1 Hz), 2H); 7.33 (t (7.6 Hz), 2H); 5.90 (m, 1H); 5.30 (d (17.3 Hz), 1H); 5.19 (d (9.4 Hz), 1H); 4.59 (d (5.2 Hz), 2H); 4.28 (m, 4H); 2.89 (dd (4.9, 20 13.5 Hz), 1H); 2.79 (m, 1H); 2.52 (t (7.3 Hz), 2H); 2.29 (t (7.3 Hz), 2H); 1.73 ppm (m, 2H). 13C NMR (d 6 -DMSO, 75MHz): 174.4, 170.9, 156.3, 144.1, 141.1, 132.6, 128.0, 127.4, 125.6, 120.5, 118.4, 66.2, 60.1, 54.5, 47.0, 32.8, 32.7, 31.1, 24.7 ppm. 25 Example 11 Coupling to acid of example 10 to resin Commercially available N-Fmoc hydroxylamine 2-chlorotrityl resin (0.77 mmol/g, 10 g, 7.7 mmol) was shaken gently with 1:1 piperidine:DMF (30 mL) over night, and then flow washed with DMF for 1 minute. In a separate flask HATU (3.0 g, 7.8 mmol) was added to a solution of acid of example 10 (3.7 g, 7.8 mmol) and 30 DIPEA (5.3 mL, 31.2 mmol) dissolved in DMF (10 mL), and the resulting solution stirred gently for 5 minutes. The HATU activated acid was then added in one portion to the deprotected resin, and the resin was shaken gently for 1 hour. After washing the resin well with DMF, the resin loading was determined WO 2005/051901 PCT/AU2004/001667 63 to be 0.46 mmol/g (70%) (LRMS m/e calc. for C 25

H

29

N

2 0 6 S (MH*) 485.6, obs. 485.1). The unreacted resin was then acylated by addition of a solution of acetic anhydride (842 mg, 7.8 mmol) and DIPEA (5.3 mL, 31.2 mmol) in DMF (20mL) with shaking for 2 minutes, followed by thorough washing with DMF. 5 Example 12 Removal of the allyl protecting group The resin of example 11 was flow washed with DCM for 2 minutes, and then shaken in DCM (30 mL) for a further 10 minutes. An argon stream was introduced, and the resin and DCM degassed for 5 minutes. DMBA (1.2 g, 7.9 10 mmol) was added, and bubbling continued for a further minute to ensure thorough mixing. Pd(PPh 3

)

4 (270 mg, 0.23 mmol) was added to the resin, the flask wrapped in aluminum foil, and after a further 30 seconds of degassing the argon stream was removed, and the resin shaken gently for 1 hour. The resin was flow washed successively with DCM, DMF, and DCM, before drying under 15 high vacuum. The resin loading was determined to be 0.45 mmol/g (LRMS m/e calc. for C 22

H

25

N

2 0 6 S (MH*) 445.5, obs. 445.2). Example 13 6-lodo-hexanoic acid tert-butyl ester: 6-Bromo-hexanoic acid (10 g, 51.3 20 mmol) was dissolved in 1,4-dioxane (30 mL) in a pressure vessel and cooled in a dry-ice bath (acetone). Isobutylene (30 mL) was added to the solution followed by H 2

SO

4 (0.5 mL). The vessel was closed and the mixture was stirred at RT for 48 hrs before it was poured into a separatory funnel with sat. NaHCO 3 (aq) (150 mL), extracted with diethyl ether (3x150 mL) and washed with brine 25 (2x150 mL). The organic phase was dried (MgSO 4 ) and evaporated and further dissolved in THF (200 mL). Nal (30.7 g, 205 mmol) was added to the reaction flask and the mixture was refluxed for 16 hrs. When the reaction mixture had cooled to RT, diethyl ether was added to the solution which made most of the salt precipitate. The salt was filtered off with a sintered glad funnel and the 30 solvent was poured into a separatory funnel, ectracted with diethyl ether (3x200 mL) and washed with brine (2x200 mL). The organic phase was dried (MgSO4), evaporated and purified by chromatography (petroleum ether: ethyl acetate, 9:1) to give a yellow oil in 90% yield over two steps. 1 H NMR (CDCl3, 600 WO 2005/051901 PCT/AU2004/001667 64 MHz): 1.40-1.43 (m, 4H), 1.43 (s, 9H), 1.56-1.62 (m, 2H), 1.79-1.85 (m, 2H), 2.21 (t, 2H, J = 7.5 Hz), 3.18 (t, 2H, J = 7.0 Hz). 13 C NMR (CDCl3, 125 MHz): 7.1, 24.1, 28.3, 28.3, 28.3, 30.0, 33.3, 35.4, 80.3, 173.1. 5 Example 14 2-Acetylamino-2-ethoxycarbony-octanedioic acid 8-tert-butyl ester 1-ethyl ester: NaH (60% dispersion in mineral oil) (3.97g, 99.1 mmol) was added to a solution of diethyl acetamidomalonate (19.57g, 90.1 mmol) dissolved in DMF (150 mL). After 30 min lodo-hexanoic acid tert-butyl ester (30g, 117.2 mmol) 10 was added to the mixture and the solution was stirred at RT for 4 hrs. The reaction mixture was poured into a separatory funnel, extracted with (3x1 50 mL) diethyl ether and washed with brine (2x1 50 mL). The organic phase was dried (MgSO4), evaporated and purified by chromatography (petroleum ether: ethyl acetate, 3:1) to give a yellow oil in 93% yield. 1 H NMR (CDCl3, 600 MHz): 1.08 15 1.13 (m, 2H); 1.24 (t, 6H, J = 7.1 Hz), 1.28-1.33 (m, 2H), 1.42 (s, 9H), 1.52-1.57 (m, 2H), 2.03 (s, 3H), 2.16 (t, 2H, J = 7.2 Hz), 2.29-2.32 (m, 2H), 4.23 (q, 4H, J = 7.1 Hz), 6.77 (bs, 1H). ). 13 C NMR (CDCI3, 125 MHz): 14.2, 23.2, 23.6, 25.1, 28.3, 28.9, 32.2, 35.5, 60.6, 62.7, 66.7, 80.2, 168.4, 169.1, 173.2. 20 Example 15 2-Acetylamino-octanedioic acid 8-tert-butyl ester 1-ethyl ester: LiCl-H20 (622 mg, 14.5 mmol) and H20 (347 pL, 19.3 mmol) was added to a solution of 2-Acetylamino-2-ethoxycarbonyl-octanedioic acid 8-tert-butyl ester 1-ethyl (3.736 g, 9.64 mmol) dissolved in DMSO (50 mL). The mixture was heated to 25 150 oC for 16 hrs then extracted with diethyl ether (3x1 00 mL) and washed with brine (2x100 mL). The organic phase was dried (MgSO4), evaporated and put on high vacuum for 10 hrs to give the product in 98% yield as a yellow oil. 1 H NMR (CDCl3, 600 MHz): 1.27 (t, 3H, J = 7.2 Hz), 1.28-1.33 (m, 2H), 1.42 (s, 9H), 1.53-1.58 (m, 2H), 1.62-1.67 (m, 2H), 1.79-1.84 (m, 2H), 2.01 (s, 3H), 2.18 30 (t, 2H, J = 7.6 Hz), 4.19 (q, 4H, J = 7.3 Hz), 4.55-4.59 (m, IH), 6.08 (d, IH, J = 7.7 Hz). 13 C NMR (CDCI3, 125 MHz): 14.3, 23.4, 25.0, 25.0, 28.3, 28.3, 28.8, 32.6, 35.5, 52.3, 61.6, 80.2, 170.0, 172.9, 173.2.

WO 2005/051901 PCT/AU2004/001667 65 Example 16 2-Acetylamino-octanedioic acid 8-tert-butyl ester: LiOH-H20 (1.79g, 42.5 mmol) was added to 2-Acetylamino-octanedioic acid 8-tert-butyl ester 1-ethyl ester (8.93g, 28.4 mmol) dissolved in 100 mL of H20:EtOH (1:1). The pH was 5 made neutral by citric acid (aq) after ca 1 hr and the EtOH was removed by evaporation. The solution was the poured into a separatory funnel, extracted with EtOAc (3x150 mL) and washed with brine (2x150 mL). The organic phase was dried (MgSO4), evaporated and purified by chromatography (petroleum ether: ethyl acetate, 1:1) to give a pale yellow oil in 93% yield. 1 H NMR (CDCl3, 10 600 MHz): 1.30-1.38 (m, 2H), 1.45 (s, 9H), 1.55-1.62 (m, 2H), 1.64-1.76 (m, 3H), 1.87-1.93 (m, 1 H), 2.06 (s, 3H), 2.22 (t, 2H, J = 7.4 Hz), 4.56-4.61 (m, 1 H), 6.30 (d, 1H, J = 7.3 Hz). 13 C NMR (CDC13, 151 MHz): 23.0, 24.7, 24.8, 28.1, 28.5, 31.7, 35.3, 52.3, 80.3, 170.9, 173.4, 175.3. 15 Example 17 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-octanedioic acid 8-tert-butyl ester: 2-Acetylamino-octanedioic acid 8-tert-butyl ester (7.5 g, 26.2 mmol) was dissolved in phosphate buffer (0.1 M, pH 7.2, 500 mL), and the pH adjusted to 7.2 by addition of 2M NaOH. The resulting solution was warmed to 390C, and 20 CoCl2.6H20 (75 mg) was added with gentle shaking. Acylase I (aspergillus melleus, 375mg) was added to the solution, and the reaction was left to sit 48 hrs at 390C. Analysis of an aliquot of the solution by 1 H NMR indicated a 1:1 mixture of the amine and the acetamide. The solvent was removed to about half the volume by evaporation and 250 mL of THF was added. NaHCO3 (4.4 g, 25 52.4 mmol) and FMOC-Succinate (4.6, 13.7 mmol) was added to the solution and the mixture was stirred for 2 hours. The solvent was removed under reduced pressure, and the residue suspended in EtOAc (300 mL), and washed successively with water, I M HCI, saturated NaHCO3 solution and brine. The organic layer was dried (MgSO4), evaporated and purified by chromatography 30 (petroleum ether: ethyl acetate, 2:1) to give a pale yellow oil in 45% yield. 1 H NMR (CDC13, 600 MHz): 1.35-1.44 (m, 4H), 1.45 (s, 9H), 1.59-1.62 (m, 2H), 1.69-1.73 (m, 1H), 1.88-1.92 (m, 1H), 2.22 (t, 2H, J = 7.4 Hz), 3.92 (bs, 1H), 4.23 (t, 1H, J = 7.0 Hz), 4.38-4.45 (m, 3H), 5.33 (d, IH, J = 8.2 Hz), 7.32 (dd, WO 2005/051901 PCT/AU2004/001667 66 2H, J = 7.4, 7.3 Hz), 7.41 (dd, 2H, J= 7.4 Hz), 7.61 (m, 2H), 7.77 (d, 2H, J = 7.5 Hz). 13 C NMR (CDCl3, 151 MHz): 24.9, 25.1, 28.3, 28.7, 32.3, 35.6, 47.4, 53.8, 67.3, 80.5, 120.2, 125.3, 127.4, 128.0, 141.5, 143.9, 156.3, 173.6, 176.4. 5 Example 18 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-octanedioic acid I -allyl ester 8 tert-butyl ester: Allyl bromide (1.74 g, 14.4 mmol) was added in one portion to a suspension of NaHCO3 (4.4 g, 52.4 mmol)) and the ester from example 17 (5.5 g, 11.8 mmol) in DMF (200 mL). The resulting solution stirred for 30 10 minutes, and then the solvent was removed under reduced pressure. The resulting residue was dissolved in EtOAc (500 mL) and washed successively with water and brine (2x200 mL). The organic layer was dried (MgSO4), and solvent removed under reduced pressure to provide the title allyl ester as a yellow oil in 92% yield. 1 H NMR (CDCl3, 600 MHz): 1.31-1.40 (m, 4H), 1.45 (s, 15 9H), 1.56-1.62 (m, 2H), 1.67-1.73 (m, 1H), 1.85-1.90 (m, IH), 2.21 (t, 2H, J = 7.5 Hz), 4.24 (t, IH, J = 7.1 Hz), 4.40-4.42 (m, 3H), 4.66 (bs, 2H), 5.27-5.37 (m, 2H), 5.91-5.93 (m, 1H), 7.33 (dd, 2H, J = 7.5 Hz), 7.41 (dd, 2H, J = 7.5 Hz), 7.60-7.62 (m, 2H), 7.78 (d, 2H, J = 7.6 Hz). 13C NMR (CDCI3, 151 MHz): 25.0, 25.1, 28.3, 28.8, 32.7, 35.6, 47.4, 54.1, 66.2, 67.2, 80.3, 119.2, 120.2, 125.9, 20 127.3, 127.9, 131.7, 141.5, 144.0, 144.1, 156.1, 172.5, 173.2. Example 19 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-octanedioic acid 1-allyl ester: Tert-butyl ester from example 18 (4.0 g, 7.83 mmol) was stirred in 9:1 TFA:DCM 25 (50 mL) for 30 min. The solvent was removed under reduced pressure, and the residue purified by flash chromatography (petroleum ether: ethyl acetate, 2:1) to provide the title acid as a white solid in 89% yield. 1 H NMR (CDCl3, 600 MHz): 1.26=7-1.42 (m, 4H), 1.63-1.70 (m, 3H), 1.86-1.88 (m, 1H), 2.35 (t, 2H, J = 7.4 Hz), 4.24 (t, 1H, J = 7.0 Hz), 4.41-4.42 (m, 3H), 4.66 (bs, 2H), 5.27-5.37 (m, 30 2H), 5.91-5.93 (m, 1H), 7.33 (dd, 2H, J = 7.4 Hz), 7.41 (dd, 2H, J = 7.5 Hz), 7.60-7.62 (m, 2H), 7.78 (d, 2H, J = 7.6 Hz). 13C NMR (DMSO, 125 MHz): 24.3, 24.8, 28.5, 32.4, 33.7, 47.1, 53.8, 65.9, 67.0, 118.9, 119.9, 125.0, 127.0, 127.7, 131.4, 141.3, 143.7, 143.8, 155.9, 172.3, 179.1.

WO 2005/051901 PCT/AU2004/001667 67 Example 20 Coupling of acid to resin: Commercially available N-Fmoc hydroxylamine 2 chlorotrityl resin (0.77 mmol/g, 7.54 g, 5.81 mmol) was shaken gently with 1:1 5 piperidine:DMF (20 mL) over night, and then washed through with DMF 10 times. In a separate flask, HATU (2.26 g, 6.10 mmol) was added to a solution of 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-octanedioic acid I -allyl ester (3.14 g, 7.0 mmol) and DIPEA (5.06 mL, 29.0 mmol) dissolved in DMF (10 mL), and the resulting solution stirred gently for 10 minutes. The HATU activated acid was 10 then added in one portion to the deprotected resin, and the resin was shaken gently for 1 hour. After washing the resin well with DMF, the resin loading was determined to be 0.522 mmol/g (91%) (LRMS m/e calc. for C26H30N206 (MH+) 467.2, obs. 467.2). The unreacted resin was then acylated by addition of a solution of acetic anhydride (842 mg, 7.8 mmol) and DIPEA (5.3 mL, 31.2 15 mmol) in DMF (20mL) with shaking for 2 minutes, followed by thorough washing with DMF. Example 21 Removal of the allyl ester: The resin was flow washed with DCM for 2 20 minutes, and then shaken in DCM (30 mL) for a further 10 minutes. A nitrogen stream was introduced, and the resin and DCM degassed for 5 minutes. DMBA (0.80 g, 5.12 mmol) was added, and bubbling continued for a further minute to ensure thorough mixing. Pd(Ph3)4 (493 mg, 0.43 mmol) was added to the resin, the flask wrapped in aluminum foil, and after a further 30 seconds of degassing 25 the nitrogen stream was removed, and the resin shaken gently for 1 hour. The resin was flow washed successively with DCM, DMF, and DCM, before drying under high vacuum. (LRMS m/e calc. for C23H26N206 (MH+) 427.2, obs. 427.1). 30 The products of examples 12 and 21 were subjected to the general procedures outlined in examples 2-4 with variations made to the amine moiety used for coupling to the acid in example 2 and the acid moiety used for reaction in example 3 to produce the compounds given in the following tables. For example utilising benzylamine as the amine used according to the procedure in WO 2005/051901 PCT/AU2004/001667 68 example 2 and by using a number of acids as the coupling moiety according to the general procedure of example 3 the compounds in table I were produced as examples 22-58. Similarly, by utilising 4-dimethylamino benzoic acid as the coupling moiety according to the general procedure of example 3 and varying 5 the amine used according to the procedure in example 2 the compounds in table 2 were produced as examples 59-96. Following similar methodology using cinnamic acid as the coupling moiety according to the general procedure of example 3 and varying the amine used 10 according to the procedure in example 2 the compounds in table 3 were produced as examples 97-102. Similarly, by utilising 4-dimethylamino benzoic acid as the coupling moiety according to the general procedure of example 3 and varying the amine used 15 according to the procedure in example 2 the compounds in table 8 of examples 103-121 were produced. Likewise, by using the 7-substituted 2-amino-heptanoate (21) and varying the acid as the coupling moiety according to the general procedure of example 3, or 20 by varying the amine used according to the procedure of example 2 the compounds in table 4 of examples 122 to 168 were produced. 25 30 WO 2005/051901 PCT/AU2004/001667 69 Table 1. HPLC Retention Time and HRMS Data for Compounds of Examples 22 57 HO H O N H

R

7 X H S H O OH 0 5 Compound R 7 -X RpHPLC RT-grad HRMS MS of Example RT-Iso (min) nin) (g/lmol) theoretical N 22 N 9.17 17.04 459.2051 459.2061 00' 23 2.32 16.66 445.1909 445.1904 24 7.25 24.56 494.0742 494.0744 25 12.00 26.57 492.1987 492.1987 26 - 7.45 24.69 444.1989 444.1952 0 0 27 o 11.46 26.27 521.1745 521.1741 11.41 18.91 468.1143 468.1155 WO 2005/051901 PCT/AU2004/001667 70 28 F 0 29 F 10.87 18.61 434.1528 434.1545 F 00 30 11.60 10.97 476.1867 476.1850 -O 31 9.39 17.34 448.1538 448.1537 HPOHo 32 ~ /10.15 17.96 461.1504 461.1490 33 4.48 21.77 422.1211 422.1203 0 34 9.25 17.00 406.1419 406.1431 0 35 N3.44 19.79 418.1574 418.1544 35 36 7.80 14.60 417.1593 417.1591 37 7.87 24.99 466.1816 466.1795 -0 38 7.53 24.77 466.1791 466.1795 20.93 21.72 482.1759 482.1744 WO 2005/051901 PCT/AU2004/001667 71 39 HO ,0 40 6.26 23.94 455.1744 455.1748 H 41 02N O 10.69 18.42 475.1672 475.1646 42 11.92 26.49 506.2143 506.2108 43 c 17.66 21.09 506.2098 506.2108 -- OH 44 8.81 25.38 522.2088 522.2057 45 7.60 24.78 480.1955 480.1952 0 46 11.46 18.94 444.1950 444.1952 0 47 11.21 18.83 474.2058 474.2057 0 48 \/ 5.95 23.67 442.1830 442.1795 49 7.13 24.49 458.2127 458.2108 50 0 5.53 22.92 410.2127 410.2108 WO 2005/051901 PCT/AU2004/001667 72 0 51 5.46 23.01 422.2131 422.2108 Br 52 8.89 16.60 380.1638 380.1639 53 9.72 17.54 394.1790 394.1795 54 10.19 17.96 408.1949 408.1952 55 8.81 16.38 380.1640 380.1639 56 N 7.72 24.85 423.1701 423.1697 57 'Q-oj-jj? 0.6 17.51 434.1388 434.1381 0 WO 2005/051901 PCT/AU2004/001667 73 Table 2. HPLC Retention Time and HRMS Data for Compounds of Examples 59-96 H 0 0 1

H

3 C-N S OH 1 0' CH3 5 Compound Y RT-Iso RT-grad HRMS MS of Example (min} (m) (g/mol theoretical 59 7.66 15.36 488.2301 488.2326 60 N- 8.30 18.23 487.2025 487.2010 YCH 61 8.83 25.38 521.2199 521.2217 -- NH 62 9.75 21.61 521.2237 521.2217 63 0 9.98 20.16 503.1969 503.1959 HN 64 12.01 20.05 535.2393 535.2374 65 10.56 18.97 495.2058 495.2061 66 8 N11 10.87 19.75 499.2396 499.2374 67 9.25 20.55 499.2396 499.2374 9.77 17.95 496.2005 496.2013 WO 2005/051901 PCT/AU2004/001667 74 68 H 69 11.10 19.18 502.1590 502.1577 NH 70 N 8.85 19.98 501.2148 501.2166 0 OH NH 71 10.88 23.21 545.2228 545.2217 H 12.64 72 N 24.48 545.2228 545.2217 73 9.15 20.57 459.2074 459.2061 74 10.27 22.44 549.2547 549.2530 75 ' 11.06 23.10 509.2230 509.2217 O H 76 9.71 21.45 565.2452 565.2479 77 -N 7.56 15.14 446.1773 446.1791 HN- 78 7.76 16.03 446.1776 446.1791 79 HN 7.67 15.65 460.2009 460.2013 N\/ 80 N N- 7.38 14.34 460.2009 460.2013 81 ( N - 8.01 17.79 460.2009 460.2013 82 H 7.46 14.58 460.2009 460.2013 WO 2005/051901 PCT/AU2004/001667 75 83N, 10.07 18.31 473.2227 473.2217 H 84 8.76 19.55 551.1312 551.1322 k Br H 85 Br N. 8.98 20.06 551.1315 551.1322 H 86 Br ' 11.28 23.26 551.1305 551.1322 87 10.26 22.37 527.2697 527.2687 88 8.91 19.92 465.2521 465.2530 H 89 9.40 17.12 437.2206 437.2217 90 NQK 8.13 17.76 542.2802 542.2796 91 7.95 16.92 437.2199 437.2217 92 N" 9.79 21.65 503.2699 503.1697 93 HO 8.34 15.38 455.2344 455.2323 94 H 8.52 16.72 439.2347 439.2374 95 N 7.88 16.54 464.2339 464.2321 96 > N" 8.87 19.50 425.2194 425.2217

H

WO 2005/051901 PCT/AU2004/001667 76 Table 3. HPLC Retention Time and HRMS Data for Compounds of Examples 97-102 z NO H H 0 N OH 5 0 Compound z RT-Iso RT-grad HRMS (q/mol) MS of Example rd (mM theoretical 8.21 18.84 429.1610 429.1591 HN- 98 7.95 17.10 429.1610 429.1591 HN 99 8.10 18.02 443.1610 443.1591 N 7.82 17.63 443.1611 443.1591 N-1-- 7.73 15.47 443.1610 443.1591 102 8.03 18.09 443.1612 443.1591 10 WO 2005/051901 PCT/AU2004/001667 77 Table 4. HPLC Retention Time and HRMS Data for Selected Compounds of Examples 122-168 H o

R

7 N H 0 NH-OH 0 5 RT- RT Compound R - T HRMS MS of Example RR4ISO Grad (/~ hoeia om n(m) (cRm l) theoreical 122 N 441.2496 N 4129 123 441.2496 124 1)441.2496 125 481.2809 126 3.88 20.23 478.2456 478.2449 N - ' 127 N 0N 442.2449 128 509.3122 129 505.2809 H 130 3.61 21 437.2206 437.2183 H 131 - N437.2206 437.2183

N

WO 2005/051901 PCT/AU2004/001667 78 132 6.81 23.10 474.2148 474.2136 Nl H 133 388.1867 134 -~399.2027 135 U2 N 443.1925 136 B - 3.77 21.26 476.1200 476.1179 137 3.55 20.52 424.2215 424.2231 138 424.2231 139 h ..- 4.78 22.88 456.2842 456.2857 140 4.94 23.20 488.2527 488.2544 141 Nj37J 3.11 18.66 404.1641 404.1639 142 6.55 24.50 516.2501 516.2493 143 416.2180 144 368.2180 145 -379.2340

N

146 6.04 22.57 461.2174 461.2184 147 F3C 12.23 25.20 503.1899 503.1901 148 O 8.61 23.87 465.2137 465.2133 14 i1IINoiI 7.67 23.43 432.2299 431.2289 WO 2005/051901 PCT/AU2004/001667 79 150 3.09 19.55 453.2496 453.2497 151 0,N 3.17 18.46 457.2425 457.2446 F3C1 152 i N 3.32 19.80 495.2226 495.2214 153 7.43 23.41 424.2242 424.2231 154 -- 6.03* 23.74 428,2209 428.2180 155 Br 3.16 17.77 466.1968 466.1948 156 .7 941* 25.83 468.2483 468.2493 157 I/) 3.20 18.08 477.1145 477.1132 158 -- N 3.18 17.77 477.1143 477.1132 159 0 3.16 17.18 429.2146 429.2133 160 ,. I19.87 16 0* 28.42 490.2324 490.2337 164 92.2 29.07 538.1342 538.1336 162 4.71 21.51 451.2330 451.2340 N 1634 163 479.2641 479.2653 N H 164 9.23 24.22 598.3010 598.3024

CN

WO 2005/051901 PCT/AU2004/001667 80 B3r 165 15.62 25.91 515.1272 515.1289 N H 166 4.16 20.63 453.2126 453.2133 H 167 XX XX 463.2360 463.2340 N H 168 3.69 19.86 479.2420 479.2401 5 Selected chemical data for a number of the compounds in tables 1 to 3 is given as follows: Hydroxamic Acid of example 22 (R 7 = 4-Dimethylamino Benzoic Acid): 1 H NMR (de-DMSO, 500 MHz): 10.32 (s, 1H); 10.02 (s, 1H); 8.51 (t (5.9 Hz), 1H); 10 8.14 (d (8.3 Hz), 1H); 7.70 (d (8.7 Hz), 2H); 7.24 to 7.10 (m, 5H); 6.63 (d (8.7 Hz), 2H); 4.52 (m, 1H); 4.21 (d (5.9 Hz), 2H); 2.89 (s, 6H); 2.86 (obsc m (5.2 Hz)); 2.76 (dd (9.5, 13.5 Hz), 1H); 2.44 (m, 2H); 1.94 (t (7.5 Hz), 2H); 1.64 ppm (m, 2H). HRMS calc. for C 23

H

3 1

N

4 0 4 S (MH*): 459.206, Found 459.201. 15 Hydroxamic Acid of example 24 (R 7 = 4-Bromobenzoic Acid): 1 H NMR (d 6 DMSO, 500 MHz): 10.27 (s, 1H); 8.63 (d (7.9 Hz), 1H); 8.56 (t (5.5 Hz), IH); 7.76 (d (8.7 Hz), 2H); 7.61 (d, 7.9 Hz), 2H); 7.25 to 7.15 (m, 5H); 4.54 (m, 1H); 4.21 (d (5.5 Hz), 2H); 2.90 (dd (4.8, 13.5 Hz), 1H); 2.75 (dd (9.5, 13.5 Hz), IH); 2.45 (m, 2H); 1.93 (br t (7.1 Hz), 2H); 1.65 ppm (m, 2H). HRMS calc. for 20 C21H 25 BrN 3 0 4 S (MH*): 494.074, Found 494.076. Hydroxamic Acid of example 38 (R 7 = 2-Napthoic acid): 1 H NMR (ds-DMSO, 500 MHz): 10.30 (s, IH); 10.04 (s, 1H); 8.70 (d (7.9 Hz), 1H); 8.60 (t (6.3 Hz), 1H); 8.45 (s, 1H); 7.97 to 7.87 (m, 4H); 7.52 (m, 2H); 7.25 to 7.10 (m, 5H); 4.63 WO 2005/051901 PCT/AU2004/001667 81 (m, 1H); 4.25 (d (5.5 Hz), 2H); 2.95 (dd (4.8, 13.5 Hz), 1H); 2.83 (ddd (1.6, 9.5, 13.5 Hz), IH); 2.49 (m, 2H); 1.96 (m, 2H); 1.67 ppm (m, 2H). HRMS calc. for

C

25

H

28

N

3 0 4 S (MH*): 466.179, Found 466.178. 5 Hydroxamic Acid of example 40 (R 7 = 1H-indole-2-carboxylic acid): 'H NMR (d 6 -DMSO, 500 MHz): 11.52 (s, IH); 10.28 (s, IH); 8.61 (t (6.0 Hz), 1H); 8.53 (d (8.3 Hz), 1H); 7.55 (d (7.9 Hz), 1H); 7.34 (d (7.9 Hz), 1H); 7.25 to 7.20 (m, 6H); 7.10 (t (7.1 Hz), IH); 6.96 (t (7.1 Hz), 1H); 4.60 (m, IH); 4.24 (m, 2H); 2.91 (dd (5.5, 13.9 Hz), 1H); 2.77 (dd (9.5, 13.9 Hz), 1H); 2.47 (m, 2H); 1.95 (br 10 t (6.7 Hz), 2H); 1.66 ppm (m, 2H). HRMS calc. for C 23

H

2 7

N

4 0 4 S (MH*): 455.175, Found 455.171. Hydroxamic Acid of example 48 (RI = Cinnamic Acid): 1 H NMR (d 6 -DMSO, 500 MHz): 10.29 (s, IH); 8.62 (t (5.5 Hz), IH); 8.32 (d (7.9 Hz), IH); 7.47 (br d 15 (7.13 Hz), 2H); 7.37 to 7.10 (m, 9H); 6.71 (d (15.9 Hz), 1H); 4.52 (dd (7.9, 14.2 Hz), IH); 4.22 (d (6.3 Hz), 2H); 2.80 (dd (6.3, 13.5 Hz), 1H); 2.65 (dd (7.9, 13.5 Hz), 1H); 2.45 (t (7.1 Hz), 2H); 1.96 (br t (7.9 Hz), 2H); 1.65 ppm (m, 2H). HRMS calc. for C 23

H

28

N

3 0 4 S (MH*): 442.179, Found 442.176. 20 Hydroxamic Acid of example 59 (NR 6

XR

7 = 4-Dimethylamino benzylamine): 1H NMR (d 6 -DMSO, 500 MHz): 10.30 (s, 1H); 8.18 (d (7.9 Hz), 1H); 7.70 (d (8.7 Hz), 2H); 7.42 (br s, 2H); 6.84 (br s, 2H); 6.62 (d (8.7 Hz), 2H); 4.60 (m, 1H); 2.88 (s, 12H); 2.80 (m, 2H); 2.48 (m, 2H); 1.95 (m, 2H); 1.68 ppm (m, 2H). HRMS calc. for C 24

H

34

N

5 0 4 S (MH*): 488.2326, Found 488.2301. 25 Hydroxamic Acid of example 61 (NR 6

XR

7 = 4-Aminobiphenyl): "H NMR (d 6 DMSO, 500 MHz): 10.30 (s, 1H); 10.20 (s, IH); 8.24 (d (7.1 Hz), 1H); 7.72 (d (8.7 Hz), 2H); 7.65 (d (8.7 Hz), 2H); 7.55 (m, 4H); 7.35 (t (7.9 Hz), 2H); 7.24 (t (7.9 Hz), 1H); 6.64 (d (8.7 Hz), 2H); 4.66 (dd (7.9, 14.3 Hz), 1H); 2.92 (obsc in 30 (5.5 Hz)); 2.90 (s, 6H); 2.84 (dd (8.7, 13.5 Hz), 1H); 2.51 (t (7.1 Hz), 2H); 1.98 (m, 2H); 1.69 ppm (m, 2H). HRMS calc. for C 2 8

H

33

N

4 0 4 S (MH*): 521.2217, Found 521.2199.

WO 2005/051901 PCT/AU2004/001667 82 Hydroxamic Acid of example 65 (NR 6

XR

7 = 8-Aminoquinoline): 'H NMR (d-DMSO, 500 MHz): 10.54 (s, 1H); 10.29 (s, IH); 8.71 (dd (1.6, 3.9 Hz), 1H); 8.67 (d (7.9 Hz), 1H); 8.56 (d (7.9 Hz), 1H); 8.32 (dd (1.6, 8.3 Hz), 1H); 7.77 (d (8.7 Hz), 2H); 7.60 (d (7.1 Hz), 1 H); 7.52 (m, 2H); 6.70 (d (9.1 Hz), 2H); 4.75 (m, 5 1H); 3.12 (dd (4.8, 13.9 Hz), 1H); 2.92 (s, 6H); 2.88 (m, 1H); 2.47 (m, 2H); 1.97 (t (7.1 Hz), 2H); 1.69 ppm (m, 2H). HRMS cac. for C2 5

H

30

N

5 0 4 S (MH*): 495.2061, Found 495.2058. Hydroxamic Acid of example 73 (NR 6

XR

7 = Benzyl Amine): 'H NMR (d 6 10 DMSO, 500 MHz): 10.32 (s, 1H); 10.02 (s, 1H); 8.51 (t (5.9 Hz), 1H); 8.14 (d (8.3 Hz), 1H); 7.70 (d (8.7 Hz), 2H); 7.24 to 7.10 (m, 5H); 6.63 (d (8.7 Hz), 2H); 4.52 (m, 1H); 4.21 (d (5.9 Hz), 2H); 2.89 (s, 6H); 2.86 (obsc m (5.2 Hz)); 2.76 (dd (9.5, 13.5 Hz), IH); 2.44 (m, 2H); 1.94 (t (7.5 Hz), 2H); 1.64 ppm (m, 2H). HRMS calc. for C 2 3

H

3 1

N

4 0 4 S (MH*): 459.2061, Found 459.2074. 15 Hydroxamic Acid of example 96 (NR 6

XR

7 = tButyI Amine): 'H NMR (d 6 DMSO, 500 MHz): 10.28 (s, 1H); 10.00 (s, IH); 7.90 (d (8.3 Hz), IH); 7.66 (d (8.7 Hz), 2H); 7.50 (s, IH); 6.62 (d (8.7 Hz), 2H); 4.44 (m, 1H); 2.89 (s, 6H); 2.77 (dd (5.2, 13.5 Hz), 1H); 2.70 (dd (8.7, 13.1 Hz), 1H); 2.45 (m, 2H); 1.94 (t 20 (6.7 Hz), 2H); 1.64 ppm (m, 2H). HRMS cac. for C 20

H

33

N

4 0 4 S (MH*): 425.2217, Found 425.2194. 25 30 WO 2005/051901 PCT/AU2004/001667 83 Selected chemical data for a number of the compounds of examples 122 to 169 is given as follows: H o R7 N H y R4 0 NH-OH 0 Compound R R 'H NMR of Example 600 MHz 1H NMR (CDCl 3 , 500 MHz) 5 8.05 (s, 1 H), 7.69 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 7.3 Hz, 1H), 7.23 (m, 5H), N 6.66 (d, , J = 8.5 Hz, 2H), 4.72 (m, 1 H), 4.47 (dd, J = 14.6, 5.8 Hz, 1H), 4.29 (dd, J = 14.8, 5.8 Hz, 1H), 2.99 (s, 6H), 2.00 (m, 2H), 1.75 (m, 2H), 1.45-1.25 (m, 6H). 1H NMR (d 6 -DMSO, 600 MHz) 5 10.54 (s, IH), 10.32 (s, IH), 8.78 (d, J = 4.3 Hz, 1 H), 8.65 (m, 3H), 8.42 (dd, J = 8.3, 1.6 Hz, 1H), 7.86 (d, J 126 N 9.0 Hz, 1H), 7.66 (dd, J = 8.3, 1.2 N Hz, IH), 7.60 (dd, J = 8.3, 4.2 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 6.7 (d, J = 9.0 Hz, 2H), 4.61 (m, 1 H), 1.93 (t, J = 7.5 Hz, 2H), 1.49 (m, 2H), 1.48 1.45 (m, 2H), 1.31-1.23 (m, 4H). 1 H NMR (d 6 -Acetone, 500 MHz) 6 10.76 (s, 2H), 9.93 (s, 1H), 7.87 (t, J = 6.0 Hz, 1H), 7.81 (d, J =8.0 Hz, 130 ' 1H), 7.61 (d, J = 8.0Hz, 1 H), 7.3-7.1 N (m, 5H), 7.06 (t, J = 8 Hz, 1 H), 4.64 H (m, 1 H), 4.42 (d, J = 6 Hz, 2H),4.39 (s, 1H), 1.96 (m, 2H), 1.80 (m, 2H), 1.60 (m, 2H), 1.4-1.3 (m, 4H). 1 H NMR (d 6 -DMSO, 600 MHz) 6 11.65 (s, I H), 10.52 (s, 1 H), 10.32 (s, 1 H), 8.99 (d, J = 7.4 Hz, I H), 8.78 (m, 1 H), 8.65 (dd, J = 7.9, 1.1 Hz, 1H), 8.64 (s, 1 H), 8.39 (dd, J = 8.3, 132 1.6 Hz, IH), 7.69-7.66 (m, 2H), 7.60 N7.57 (m, 2H), 7.43 (d, J = 8.3 Hz, H I H), 7.39 (s, 1 H), 7.20 (t, J = 7.9 Hz, I H), 7.06 (t, J = 7.8 Hz, 1 H), 4.72 (m, 1 H), 1.93 (t, J = 7.3 Hz, 2H), 1.50 (m, 4H), 1.48-1.30 (m, 4H). 1H NMR (d 6 -Acetone, 500 MHz) 6 136 Br 9.92 (s, 2H), 7.88 (d, J = 8.5 Hz, 2H), ""a i7.84 (d, J = 6.5, Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.28 (m, 3H), 7.21 (m, 1 H), 4.62 (m, I H), 4.42 (d, J = 6 Hz, WO 2005/051901 PCT/AU2004/001667 84 2H), 2.72 (s, 1H), 1.94 (m, 2H), 1.79 (m, 2H), 1.58 (m, 2H), 1.4-1.3 (m, 4H). H NMR (d 6 -Acetone, 500 MHz) 6 9.95 (s, 1H), 7.93 (s, 1H), 7.67 (br s, 139 1 H), 7.28-7.20 (m, 5H), 6.69 (d, J = 8.0 Hz, 1H), 4.44 (m, 1H), 4.39 (d, J = 6.0 Hz, 2H), 1.99 (br s, 3H), 1.87 (m, 6H), 1.82 (m, 2H), 1.72 (m, 6H), 1.65-1.51 (m, 4H), 1.32 (m, 4H). 1 H NMR (d 6 -Acetone, 500 MHz) 6 9.91 (s, IH), 7.80 (s, IH), 7.68 (m, 2H), 7.64 (d, J = 7.5 Hz, 2H), 7.57 140 '(d, J = 8.2 Hz, 2H), 7.46-7.38 (m, 5H), 7.35-7.20 (5H), 4.44 (m, 1H), 4.37 (d, J = 6.0 Hz, 2H), 3.62 (d, J = 4.2 Hz, 2H), 1.81 (m, 2H), 1.62 (m, 2H), 1.53 (m, 2H), 1.30 (m, 4H). 1 H NMR (d 6 -Acetone, 500 MHz) 5 9.90 (s, I H), 7.85 (br s, 1 H), 7.81 141 (dd, J = 3.7, 1.1 Hz, 1 H), 7.74 (br s, 1H), 7.67 (dd, J= 5.0, 1.1 Hz, 1H), 7.29 (m, 5H), 7.21 (br s, IH), 7.12 (dd, J = 5.0 Hz, I H), 4.58 (m, 1 H), 4.41 (d, J = 6.0 Hz, 2H), 1.76 (m, 2H), 1.57 (m, 2H), 1.46-1.30 (m, 6H). 1H NMR (d 6 -Acetone, 500 MHz) 6 9.91 (s, 1 H), 7.85 (d, J = 7.8Hz, 2H), 7.77 (br s, 1 H), 7.70 (m, 4H), 7.40 (t, 142 '' J = 7.5 Hz, 2H), 7.29 (m, 5H), 7.21 br s, 1H), 6.61 (d, J = 7.6 Hz, 1H), 0. ,4.41 (d, J = 5.9 Hz, 2H), 4.33 (m, . 1H), 4.22 (d, J = 6.9 Hz, 2H), 4.17 (m, 1 H), 1.84 (m, 2H), 1.68 (m, 2H), 1.59 (m, 2H), 1.46-1.31 (m, 6H). 1 H NMR (d 6 -DMSO, 600 MHz) 6 10.46 (s, 1H), 10.31 (s, 1H), 8.86 (dd, J = 4.3, 1.7 Hz, 1 H), 8.64 (dd, J = 7.7,1.3 Hz, I H), 8.41 (dd, J = 8.3, 1.7 Hz, 1 H), 8.31 (dd, J = 8.5, 3.6 146 Hz, I H), 7.69 (dd, J = 8.3,1.3 Hz, N.- I 1H),7.59-7.55 (m, 2H), 7.50 (d, J = 15.8 Hz, I H), 7.65 (dd, J = 8.3, 4.2 Hz, I H), 7.59 (t, J = 8.0 Hz, I H), 7.44-7.7.39 (m, 3H), 6.84 (d, J = 15.8 Hz, 1H), 4.11 (m, 1H) 1.93 (t, J = 7.5 Hz, 2H), 1.64-1.58 (m, 2H), 1.46 (m, 2H), 1.34-1,27 (m, 4H). 1 H NMR (d 6 -DMSO, 600 MHz) 6 10.56 (s, 1H), 10.31 (s, 1H), 9.28 (d, J = 7.4 Hz, 2H), 8.84 (dd, J = 4.1,1.4 F3C N Hz, 1H), 8.63 (dd, J = 7.7,1.3 Hz, 147 N. 1H), 8.42 (dd, J = 8.3,1.6 Hz, 1 H), 8.12 (d, J = 7.1 Hz, I H), 7.83 (d, J 7.3 Hz, 2H), 7.69 (dd, J = 8.3, 1.2 Hz, I H), 7.63 (dd, J = 8.2, 4.2 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 4.10 (m, I H) 1.93 (t, J = 7.5 Hz, 2H), WO 2005/051901 PCT/AU2004/001667 85 1.64-1.58 (m, 2H), 1.46 (m, 2H), 1.34-1,27 (m, 4H). 1H NMR (d 6 -DMSO, 600 MHz) 6 10.46 (s, 1H), 10.31 (s, 1H), 8.86 (dd, J = 4.1,1.4 Hz, 1 H), 8.64 (d, J = 7.1 Hz, 1 H), 8.42 (dd, J = 8.3, 1.6 Hz, IH), 8.12 (d, J = 7.1 Hz, 1H), 7.69 (dd, J = 8.3, 1.2 Hz, I H), 7.66 0, N (dd, J = 8.2, 4.2 Hz, 1 H), 7.59 (t, J = 7.9 Hz, 1H), 7.37 (m, 3H), 7.30 (m, 2H), 5.01 (m, 2H), 4.10 (m, 1H), 1.93 (t, J = 7.5 Hz, 2H), 1.64-1.58 (m, 2H), 1.46 (m, 2H), 1.34-1,27 (m, 4H). 1H NMR (d 6 -DMSO, 600 MHz) 6 10.46 (s, 1H), 10.31 (s, IH), 8.86 (d, J = 3.8 Hz, 1 H), 8.64 (d, J = 7.1 Hz, S1H), 8.42 (dd, J = 8.3, 1.6 Hz, 1 H), 7.94 (d, J = 7.1 Hz, 1 H), 7.68 (dd, J 149 ON = 8.3,1.2 Hz, 1H), 7.65 (dd, J = 8.3, 4.2 Hz, 1 H), 7.59 (t, J = 8.0 Hz, 1 H), 4.16 (m, 1H), 3.88 (m, 2H), 2,41 (m, I H), 1.92 (t, J = 7.5 Hz, 2H), 1.83 (m, 2H), 1.46 (m, 2H), 1.35-1.28 (m, 4H), 0.91 (dd, J = 6.4, 3.8 Hz, 6H) 1 H NMR (d 6 -DMSO, 600 MHz) 6 10.33 (s, IH), 10.08 (s, IH), 8.36 (d, I J = 7.8 Hz, 2H), 7.56 (m, 3H), 7.35 150 N (m, 5H), 7.06 (br s, IH), 6.80 (d, J 15.8 Hz, 1H), 4.51 (m, 1H), 4.04 (br - -s, 1 H), 1.93 (t, J = 7.5 Hz, 2H), 1.72 1.58 (m, 2H), 1.46 (m, 2H), 1.36-1,27 (m, 4H). 1 H NMR (d 6 -DMSO, 600 MHz) 5 10.32 (s, 1H), 9.94 (s, 1H), 7.55 (d, J = 7.8 Hz, 2H), 7.35 (m, 5H), 7.30 151 NN (d, J = 7.8 Hz, 2H), 7.06 (br s, 1 H), O 5.02 (s, 2H), 4.10 (m, IH), 4.04 (br s, I H), 1.93 (t, J = 7.5 Hz, 2H), 1.64 1.58 (m, 2H), 1.46 (m, 2H), 1.34-1,27 (m, 4H). 1 H NMR (d 6 -DMSO, 600 MHz) 6 10.32 (s, 1H), 10.06 (s, IH), 8.8 (d, J F3C = 7.6 Hz, 2H), 8.15 (d, J = 8.2 Hz, 152 N 2H), 7.85 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 7.05 (br s, 1 H), 4.55 (m, 1 H), 4.04 (br s, 1 H), 1.93 (t, J = 7.5 Hz, 2H), 1.49 (m, 2H), 1.42 (m, 1H), 1.34-1,27 (m, 3H). 1 H NMR (d 6 -DMSO, 600 MHz) 6 10.32 (s, IH), 8.64 (s, 1H), 8.54 (t, J = 6.0 Hz I H), 8.24 (d, J = 8.4 Hz, 153 '' 1H), 7.55 (d, J = 7.2 Hz, 2H), 7.44 7.36 (m, 3H), 7.31-7.22 (m, 5H), 6.78 (d, J = 15.8 Hz, IH), 4.40 (m, 1H), 4.28 (d, J =5.5 Hz, 2H), 1.91 (t, J = 7.5 Hz, 2H), 1.69 (m, 1H), 1.56 (m, 1 H), 1.45 (m, 2H), 1.31-1.23 (m, 4H).

WO 2005/051901 PCT/AU2004/001667 86 1 H NMR (d 6 -DMSO, 600 MHz) 6 10.31 (s, 1H), 8.40 (s, IH), 7.41 (d, J = 8.1 Hz, 2H), 7.36-7.29 (m, 6H), 154 ' 7.23 (d, J = 7.5 Hz, 2H), 5.02 (d, J 0, 3.5 Hz, 2H), 4.27 (dd, J = 5.6, 3.7 Hz, 2H), 3.97 (m 1 H), 3.44 (br s, 1 H), 1.91 (t, J = 7.4 Hz, 2H), 1.69 (m, 1H), 1.56 (m, IH), 1.45 (m, 2H), 1.31-1.23 (m, 4H). 1H NMR (d 6 -DMSO, 600 MHz) 6 10.31 (s, 1 H), 8.52 (t, J = 7.2 Hz, 155C I H), 8.1 (d, J = 8.1 Hz, 2H), 7.85 (d, 155 J = 8.2 Hz, 2H), 7.64 (br s, 1 H), 14- 7.32-7.22 (m, 5H), 4.40 (m, 1 H), 4.28 (d, J = 7.2 Hz, 2H), 1.91 (t, J = 7.5 Hz, 2H), 1.77 (m, 2H), 1.47 (m, 2H), 1.37-1.26 (m, 4H). 1 H NMR (d 6 -DMSO, 600 MHz) 5 10.31 (s, 1 H), 8.25 (d, J = 8.4 Hz, 1 H), 8.16 (d, J = 7.2 Hz, I H), 7.35 156 r(m, 2H), 7.29 (m, 2H), 7.13 (m, 3H), 5.03 (m, 2H), 4.94 (m, IH), 3.97 (m, 1H), 2.71 (m, 2H), 1.91 (t, J = 7.5 Hz, 2H), 1.84 (m, 2H), 1.69-1.54 (m, 4H), 1.45 (m, 2H), 1.31-1.23 (m, 4H). 1 H NMR (d 6 -DMSO, 600 MHz) 6 10.32 (s, 1H), 8.68 (t, J = 5.6 Hz, IH ), 8.64 (d, J = 7.6 Hz, 1 H ), 8.60 (d, J B-~ = 4.8 Hz, 1H ), 8.02 (t, J= 7.4 Hz, 157 1 H ), 7.85 (d, J =6.7Hz, 2H), 7.69 (d, J = 11.0 Hz, 2H), 7.47 (m, 2H), 4.44 (d, J = 5.9 Hz, 2H), 4.42 (m, 1 H), 1.92 (t, J = 7.5 Hz, 2H), 1.77 1.73 (m, 2H), 1.47 (m, 2H), 1.36-1.26 (m, 4H) 1H NMR (d 6 -DMSO, 600 MHz) 6 10.32 (s, 1H), 8.73 (m, 3H), 8.66 (d, Br J = 7.3 Hz, 2H), 7.85 (d, J = 6.7 Hz, 158 B2H), 7.69 (d, J = 11.0 Hz, 2H), 7.65 (d, J = 4.9 Hz, 2H), 4.46 (m, 2H), 4.40 (m, 1 H), 1.92 (t, J = 7.5 Hz, 2H), 1.77-1.73 (m, 2H), 1.47 (m, 2H), 1.36-1.26 (m, 4H) IH NMR (d 6 -DMSO, 600 MHz) 5 10.32 (s, 1H), 8.69 (m, 3H), 7.61 (m, 159 '' 2H), 7.54 (d, J = 7.5 Hz, IH), 7.36 0 N 7.31 (m, 5H), 5.05 (m, 2H), 4.45 (m, 2H), 3.99 (m, 1 H), 1.92 (t, J = 7.5 Hz, 2H), 1.64 (m, 1H), 1.56 (m, 1H), 1.46 (m, 2H), 1.36-1.26 (m, 4H) 1H NMR (d 6 -DMSO, 600 MHz) 6 10.32 (s, IH), 10.12 (s, 1H), 8.64 (m, 160 1 H), 7.69 (m 2H), 7.63 (m, 3H), 7.58 (d, J = 7.8 Hz, 2H), 7.44 (t, J = 7.8 Hz, 2H), 7.36 (m, 3H), 7.32 (m, 2H), 5.03 (s, 2H), 4.14 (m, 1H), 1.92 (t, J = 7.5 Hz, 2H), 1.66 (m, 1H), 1.61 (m, WO 2005/051901 PCT/AU2004/001667 87 1H), 1.46 (m, 2H), 1.37-1.26 (m, 4H) 1H NMR (d 6 -DMSO, 600 MHz) 6 10.32 (s, 1H), 10.22 (s, 1H), 8.71 (d, Br / J = 7.5 Hz, 1H), 7.87 (d, J = 8.6 Hz, 161 Br 2H), 7.70 (t, J = 9.0 Hz, 4H), 7.63 (m, 4H), 7.44 (t, J =7 .8 Hz, 2H), 7.32 (t, J= 7.9 Hz, 1 H) 4.55 (m, I H), 1.93 (t, J = 7.5 Hz, 2H), 1.80 (m, 2H), 1.49 (m, 2H), 1.43 (m, 1H), 1.37 (m, 1H), 1.26 (m, 2H) 1H NMR (d 6 -DMSO, 600 MHz) 6 10.82 (s, 1H), 10.32 (s, 1H), 8.42 (t, J = 6.0 Hz, IH), 8.02 (d, J *8.1 Hz, 162 1 H), 7.54 (d, J = 7.6 Hz, I H), 7,32 (d, J= 8.1 Hz, 1H), 7.29-7.18 (m, N 5H), 7.05 (dd, , J = 7.0, 1.1 Hz, 1H), H 6.94 (dd, , J = 7.0, 1.1 Hz, 1 H), 4.24 (m, I H), 3.56 .92 (t, J = 7.5 Hz, 2H), 1.66 (m, 1H), 1.61 (m, 1H), 1.44 (m, 2H), 1.31-1.18 (m, 4H) Biological data The cytotoxicities of the compounds of the invention were determined by 5 clonogenic survival of human cancer cells (MM96L, melanoma) and human normal cells (NFF, neonatal foreskin fibroblasts). Cells were incubated with the compounds at various concentrations of compound (0.01 - 10 ptg/mL) for 24 hours, washed, and then grown for a further four days in the absence of hydroxamic acid before determining cell survival by cell count. The final readout 10 involved staining with sulforhodamine B (SRB), a cost-effective method amenable to automation and high throughput analysis. At the technical level, "cell sensitivity" is often inferred from short term (1-2 day) observations such as apoptosis, which may not be a satisfactory model of clonogenic survival. Compounds were considered for further testing if they exhibited either potency 15 (IC 5 o 200 nM) or selectivity (SI >5) in their killing of cancer cells over normal cells. Cell Lines and Culture Medium. All cell lines used in this study have been described previously (Parsons et al., 1986; Todaro et al., 1980; Glenn et al., 20 2004). All cell lines were cultured in 10% heat-inactivated foetal calf serum (CSL, Australia) in RPMI 1640 medium supplemented with 100 U/mL penicillin, WO 2005/051901 PCT/AU2004/001667 88 100 pg/mL streptomycin, and 3 mM HEPES at 5% C02, 99% humidity at 37 0 C. Primary human fibroblasts were obtained from neonatal foreskins and cultured in the above medium. Routine mycoplasma tests were performed using Hoechst stain' and were always negative. 5 Cell Survival Assay. Cells were plated into 96-well microtitre plates at 5 x 103 cells / well, and allowed to adhere overnight. Test compounds were added to culture rnedium at the indicated concentrations, and plates incubated in the above conditions for 24 hours. Following this incubation period, compounds 10 and media were removed, and replaced with fresh culture medium. Cells were then grown for a further 72 hours before assay using sulforhodamine B (SRB; Sigma, St. Louis, MO) as previously described. Briefly, the culture medium was removed from the 96-well microtitre plates and the plates washed twice with phosphate buffered saline (PBS), before the cells were fixed with methylated 15 spirits for 15 minutes. The plates were then rinsed with tap water and the fixed cells stained with 50 jpL / well of SRB solution (0.4% sulforhodamine B (w/v) in 1% (v/v) acetic acid) over a period of 1 hour. The SRB solution was then removed from the wells and the plates rapidly washed two times with 1 % (v/v) acetic acid. Protein bound dye was then solubilised with the addition of 100 tL 20 of 10 mM unbuffered Tris, and incubated for 15 min at 250C. Plates were then read at 564 nm on a VERSA max tuneable microplate reader (Molecular Devices, Sunnyvale, CA). The results of the biological test results on each of the compounds is as given in 25 the following tables. 30 WO 2005/051901 PCT/AU2004/001667 89 Table 5. Activity of Compounds of Examples 22-58 H O

R

7 X N H O OH 0 5 Compound R 7 -X Log D 7 .0 ICao NFF (pM) IC 5 o MM96L Selectivity of Example (AM) 22 \ 2.1 0.35±0.07 0.14±0.09 2.5 N 23 1.6 8.3±0.8 1.7±0.1 4.9 -o 24 2.7 0.83±0.09 0.02±0.1 4.2 Br 25 3.5 2.8±0.2 0.9±0.1 3.1 26 / 2.8 10.9±0.9 2.0±0.4 5.5 0 0 27 3.0 30±1 24±3 1.3 28 2.2 >100 28±3 >3 Di WO 2005/051901 PCT/AU2004/001667 90 0 29 1.5 26±1 5.2±0.6 5.0 -0 30 1.5 4.5±0.6 1.7±0.3 2.6 -o 31 0.7 4.5±0.6 32±3 0.14 H OH 32 0.9 >100 10.6±0.1 >10 S020 33 1.8 9±1 2.5±0.2 3.6 34 0 0.5 22±1 7.2±0.2 3.1 35 0.4 62±5 19±2 3.3 N0 36 0.1 >100 12.8±0.8 >8 0 37 2.8 5.3±0.6 6.3±0.6 0.8 38 0 2.8 1.14±0.05 0.6±0.2 1.9 39 2.5 >100 13±2 >8 H0 40 1.4 0.8±0.2 0.13±0.09 6.2 WO 2005/051901 PCT/AU2004/001667 91 ,0 H 41 0 2 N 1.0 >100 12±1 >8 42 3.5 21±2 12±3 1.8 0 43 0 -0 2.6 22±2 9.3±0.3 2.4 44 0 2.9 9.3±0.7 1.8±0.2 5.2 1 - OH 45 2.8 15±1 4.1±0.7 3.7 46 0 1.5 21±3 7.4±0.5 2.9 47 0 1.4 16±1 8±1 2.0 48 0 2.2 0.8±0.2 0.2±0.1 4.0 49 o 2.6 11±2 5±1 2.2 50 1.8 25±4 7±2 3.6 51 o 2.4 10±1 5±2 2.0 Br WO 2005/051901 PCT/AU2004/001667 92 52 0 0.4 >100 11±0.7 >9 53 0 0.8 22±1 11±1 2.0 54 1.0 >100 21±3 >5 55 0 >100 21±2 >5 56 0.9 9.6±0.9 4.4±0.3 2.2 0= H 57 0o 0.6 >100 45±7 >2 H 0 58 / 0 1.7 >100 <1 00 >1 0 5 10 15 WO 2005/051901 PCT/AU2004/001667 93 Table 6. Activity of Compounds of Examples 59-96 H 0 0 1 - Y H H3C-N S OH 1 0O 5

CH

3 IC50 (pM) Selectivity Compound Y Log D 7

.

0 of Example NFF MM96L 59 1.6 0.6±0.1 0.1±0.1 6.0 60 1.3 1.60±0.08 0.55±0.05 2.9 N-' H 61 3.6 0.32±0.05 0.17±0.05 1.9 62 -NH 3.6 4.4±0.6 2.1±0.2 2.1 63 2.2 2.8±0.1 0.96±0.07 2.9 HN 64 4.5 6.8±0.4 3.5±0.2 1.9 65 2.9 5.9±0.7 1.3±0.1 4.5 WO 2005/051901 PCT/AU2004/001667 94 66 3.2 2.2±0.3 0.5±0.1 4.4 67 2.4 2.2±0.2 0.20±0.1 11 71 2.5 3.0±0.3 0170.03 5.0 1 69 9 \/NH 0.2 3.3±0.3 1.3±0.1 2.5 N 70 1.3OH 0.6 8.2±0.8 0.90±0.05 9.1 NH 71 N I,4.1 2.2±0.3 1.7±0.3 1.3 72 H 4.1 1.14±0.06 0.55±0.07 2.1 73 1.3 0.35±0.07 0.14±0.09 2.5 74 3.1 15.3±0.6 2.3±0.2 6.5 75 HN 2.5 0.42±0.05 0.20±0.02 2.1 76 QH 2.2 9±3 2.1±0.2 4.3 SHN, 77 0.4 7.2±0.8 1.8±0.2 4.1 WO 2005/051901 PCT/AU2004/001667 95 78 HN- - 0.4 11±1 2.1±0.1 5.6 HN 79 N 1.2 11.20.7 1.12±0.06 10.0 80 N Q0.1 14±1 2,2±0.3 6.2 HN- 81 0.1 8.8±0.5 1.49±0.09 5.9 N- HN- 82 0.2 6.5±0.3 1.2±0.1 5.5 83 H 1.7 2.7±0.3 1.4±0.1 1.9 N, 84 H 2.6 3.3±0.3 0.7±0.2 4.7 N. 85 H 2.7 3.1±0.1 0.9±0.1 3.4 Br N. 86 BA 2.6 2.6±0.3 1.0±0.1 2.6 86Br 87 H 3.1 4.2±0.5 0.6±0.1 7.0 88 2.1 3.6±0.2 0.51±0.09 7.1 89 1.9 2.6±0.3 1.5±0.1 1.7 40yIi,, WO 2005/051901 PCT/AU2004/001667 96 90 H 0.4 1.28±0.08 1.5±0.2 0.9 'N

N

91 0.9 20±2 4.9±0.3 4.2 92 2.3 7.1±0.5 1.48±0.08 4.8 N' H 93 H 0.8 12±1 1.8±0.2 6.7 HO N 94H 1.7 7±1 0.85±0.04 8.0 95 1.4 6.0±0.8 1.3±0.2 4.5 N~) 96 >'N' 0.9 3.5±0.5 0.7±0.2 5.0 H 5 10 15 WO 2005/051901 PCT/AU2004/001667 97 Table 7. Activity of Compounds of Examples 97-102 z NO H O NOH 5 0 Compound Z Log D 7

.

0 IC50 (pM) Selectivity of Example NFF MM96L 97 0.7 1.6±0.3 0.5±0.2 3.3 98 HN- - 0.7 6.4±0.8 1 .2±0.3 5.2 HN6 99 1.5 4.0±0.6 0.6±0.2 6.5 100 0.4 1.6±0.2 0.34±0.02 4.8 N N- 101 0.4 13.2±0.7 0.9±0.2 15.1 102 .--- 0.5 4.2±0.4 0.8±0.3 5.3 N H 10 WO 2005/051901 PCT/AU2004/001667 98 Table 8. Activity of Compounds of Examples 103-121 NH N R10 O 0 0 S0 NHOH 0 5 Compound of IC50 (pM) Example R10 Log D 7

.

0 Selectivity NFF MM96 103 --- 1.44 10.12 1.38 7.30 104 1.71 8.08 1.62 5.0 105 1.02 17.03 4.26 4.0 106 H 2.05 11.84 1.18 10.0 107 -1 0.83 16.89 2.96 5.7 108 0.95 16.89 2.28 7.4 109 H-NH 2.23 2.42 0.54 4.5 110 H OH 1.96 16.10 2.98 5.4 111 4.21 1.11 0.51 2.2 112 T 3.00 14.34 2.87 5.0 113 n', 1.52 15.84 3.96 4.0 _______ _-__-N_

N-

WO 2005/051901 PCT/AU2004/001667 99 114 I'NN 1.73 12.15 1.5 8.1 N' N H H 115 3.80 1.35 0.56 2.4 116 2.41 5.57 2.23 2.5 117 H 2 N-o 2.00 5.27 1.19 4.4

NH

2 118 - 3.78 1.17 3.2

NH

2 119 19- 1.74 0.93 1.9

NH

2 120 120 - 2.32 1.02 2.4 H 121 N 121 - 11.57 1.41 8.2 5 10 15 WO 2005/051901 PCT/AU2004/001667 100 Table 9. Activity of Compounds of Examples 122-171 H 0

R

7 N H 0 R O NH--OH 0 Compound IC50(uM) Of Example R 7 R4 * LogD Sa NFF MM96L N - I1.6 122 NIS 2.8 12 ±2 7.8 ±0.3 123 N R 2.8 1.0±0.1 8 6.0 ±0.08 12a S 2.8 0.87 ±0.07 0 27 12 N 3.6 1.81 ±0.07 6.0 00 C -402 H 126 S 2.8 0.57±007 2 28 N ±-0.01 127 NI S 1.9 33 ±5 36 9.1 N . ±0.4 NO 0.9 128 NI S 4.1 3.0 ±0.3 ±02 35 129 - j S 3.4 1.6 ±0.2 0.9 1.7 N ~.. -- ±0.2 H 130 ~ "/- I~S 2.45 1.260 0.252 5.0 N 131 R 2.45 0.572 0.080 7.1 WO 2005/051901 PCT/AU2004/001667 101 132 S 2.96 0.337 0.021 16 N r 0.2 133 a 1.1 4.6±0.4 23 c ±0.8 134> 1.02.88 2.5 N C 02 N r 135 2N0.9 9 ±2 6 i1 1.5 136 S 3.02 5.864 1.994 4.2 137 S 2.67 4.014 0.46 8.7 138 R 2.67 1.145 0.252 4.5 139 S 3.13 7.133 3.951 1.8 140 S 4.04 5.127 2.358 2.2 141 77. l%*J S 2.05 5.204 0.892 5.8 142 S 4.45 5.365 3.199 1.7 0', J7 ~r 0.97 143 a 1.3 1.3±0.1 1.3 0 +±0.08 N c r 1.5 144 0a 1.0 4.4 ±0.5 +02 2.9 145 14a 1.0 12 ±1 9 ±2 1.3 146 S 3.18 1.24 0.021 58.9 147 F3C S 3.81 0.696 0.258 2.7 148 0 S 2.96 0.452 0.043 10.5 WO 2005/051901 PCT/AU2004/001667 102 149 oIIiIN) S 2.62 0.081 0.023 3.5 150 N S 2.30 0.240 0.165 1.5 151 0,f~IN S 2.77 0.650 0.610 1.1

F

3 C 152 FCS 3.62 0.404 0.222 1.8 153 S 2.67 0.990 0.731 1.4 154 S 2.45 1.520 1.520 1 155 TJ J) S 3.29 1.611 0.665 2.4 156 0, S 2.89 1.710 1.710 1 157 Br S 1.92 2.094 1.152 1.8 158 B S 1.79 5.237 0.837 6.3 159 O S 1.22 23.34 4.32 5.4 160 * .. '- S 4.76 2.209 0.331 6.7 Br 161 Br S 5.34 0.185 0.074 2.5 162 S 2.30 >2.219 0.332 >7 163 S 3.27 7.034 1.845 3.8 H 164 S 3.34 9.759 NA

HN

WO 2005/051901 PCT/AU2004/001667 103 Br 165 S 3.25 1.940 0.485 4.0 166 S 2.02 2.209 0.331 6.7 H 167 S 2.89 10.377 3.242 3.2 N 168 S NA NA Selectivity Index = IC5o (NFF)/ IC5o (MM96L). A number of the more active compounds were also tested for cytotoxicity and 5 cytoselectivity against six other human cancer cell lines two melanoma (SkMel28, D04), prostate (DU145), breast (MCF-7), and ovarian (JAM, C-80 13S). For comparison their results are also shown for MM96L and NFF cell lines. The results of these additional tests are given in table 9. 10 Table 10. Cytotoxicity of Selected Compounds for Various Cancer Cell Lines Cell line IC50 (ptM) Compound NFF MM96L SkMel D04 DU145 MCF7 JAM C18013S 22 0.35 (7) 0.14 (9) 3.0 (3) 2.0 (3) 0.61 (4) 0.59 1.24 0.7(2) (5) (6) 24 0.83 (9) 0.2 (1) 5.7 (4) 3.5 (2) 3.8 (4) 1.16 2.0 (2) 1.5 (3) (2) 40 0.8 (2) 0.13 (9) 1.7 (2) 1.3 (4) 0.4 (4) 0.84 0.75 0.4 (3) (9) (8) 44 0.8 (2) 0.2(1) 2.5 (1) 2.1 (3) 1.70 (3) 0.7 (2) 1.8 (1) 0.6 (5) 59 0.60 0.10 1.09 1.05 0.33 0.39 0.43 0.39 61 0.32 0.17 1.11 0.83 0.37 0.48 0.60 0.38 WO 2005/051901 PCT/AU2004/001667 104 67 2.20 0.20 2.59 2.73 1.06 0.96 1.47 1.24 70 8.20 0.90 6.14 7.12 3.76 3.30 7.22 2.50 78 3.60 0.51 2.33 2.48 1.06 0.97 2.30 1.36 Table 11. Antiproliferative Potencies of Compound 1 24. Cell Linea IC 50 (tM) Selectivityb MM96L 0.13 ±0.02 6.7 MM229 0.60 ± 0.08 1.5 MM329 0.06 ±0.04 15 MM470 0.09 ±0.07 10 MM604 0.01 ± 0.01 87 Mel RM 0.95 ± 0.07 0.9 Mel FH 0.08 ±0.04 11 SK Mel 28 0.06 ±0.04 15 D04 0.12 ±0.03 7 D14 0.26 ±0.08 3 D11 0.3 ±0.2 3 D17 0.06 ± 0.02 15 LSP M2 0.45 ± 0.05 2 AF-6 0.30 ± 0.03 3 AO7 RM 0.18 ±0.07 5 A2058 0.10 ±0.02 9 HeLa 0.09 ±0.01 10 NFF 0.87 ± 0.07 1 a NFF, neonatal foreskin fibroblasts; MM96L, 229, 329, 470, 604, Mel RM and 5 FH, SK-Mel-28, D04, 11, 14, 17 melanoma; DU145, prostate; MCF-7 breast; JAM, CI-80-13S, ovarian. Standard deviations are in parentheses. b A more comprehensive list of non-melanoma cell lines to be added Selectivity Index =

IC

50

(NFF)/IC

50 (cancer cell line), recognizing that the IC50 for NFFs is an underestimate because many cells are selectively differentiated to a non 10 proliferating phenotype.

WO 2005/051901 PCT/AU2004/001667 105 Table 12. Cytoselectivities (nM) For Six Antitumour Compounds (S and R enantiomers) In Different Cancer Cell Linesa Cancer 126 132 146 148 149 161 Cell S R S R S R S R S R S R A549 148 191 69 121 73 196 248 104 291 453 335 18619 DU145 61 52 22 33 30 63 131 39 130 221 149 18619 HOP62 137 147 63 63 65 133 226 65 267 314 261 18619 HT29 178 199 79 238 99 272 334 139 360 488 307 18619 MCF-7 35 40 19 42 17 51 122 29 138 178 149 13033 MM96L 51 38 18 18 20 45 108 22 116 163 121 18619 SK- 73 57 33 43 37 87 146 43 170 267 168 18619

MEL

28 SK- 32 44 18 23 29 66 70 20 100 115 102 18619 MEL-5 H520 63 188 26 180 27 152 118 46 129 337 117 18619 T-47D 45 63 19 42 20 99 93 51 198 291 197 18619 C180- 65 43 20 27 28 91 124 29 149 203 158 18619 13S JAM 85 251 48 211 49 163 194 65 221 267 182 18619 PC-3 220 387 148 148 109 543 528 269 651 2092 531 18619 Col208 223 -- b 102 -- 141 -- 122 -- 395 -- 272 a Colo208 (colon), DU145 (prostate), MCF-7 (breast), SK-MVEL-28 (melanoma), A549 5 (lung), HOP62 (lung), HT29 (colon). b Not performed. Table 13. Selectivity Index For Six Antitumour Compounds (S enantiomer), Cancer Cell Compared to NFFs. Cancer Cell 126 132 146 148 149 161 A549 4 5 17 2 0.3 0.6 DU145 9 15 41 3 0.6 1.2 HOP62 4 5 19 2 0.3 0.7 HT29 3 4 13 1.4 0.2 0.6 MCF-7 16 18 71 4 0.6 1.2 MM96L 11 19 63 4 0.7 1.5 SK-MEL-28 8 10 34 3 0.5 1.1 SK-MEL-5 18 18 43 6 0.8 1.8 H520 9 13 46 4 0.6 1.6 T-47D 13 18 63 5 0.4 0.9 C180-13S 9 17 44 4 0.5 1.2 JAM 7 7 25 2 0.4 1.0 PC-3 3 2 11 0.9 0.1 0.3 Col208 1.5 3 9 4 0.2 0.6 10 Selectivity Index = IC 50

(NFF)/IC

50 (cancer cell line), recognizing that the IC50 for NFFs is an underestimate because many cells are selectively differentiated to a non-proliferating phenotype.

WO 2005/051901 PCT/AU2004/001667 106 Histone Hyperacetylation. The more potent compounds were tested for inhibition of histone deacetylase by monitoring the acetylation state of histone H4 using Triton-acetic acid-urea gel electrophoresis. 5 One set of results is shown in figure 1 for the compounds of examples 22 and 40, showing hyperacetylation of H4. It was not necessary to quantitate histone deacetylation because the compounds inhibit HDAC activity in both normal and cancer cells and has no impact on the cytoselectivity. The known HDAC inhibitor, TSA, included for comparison, showed similar levels of 10 hyperacetylation indicated by the mobility shift of histone H4. Clearly visible in untreated cells is the non-acetylated histone H4 (lane 1, arrow A). In the extracts from cells treated with 10 pg/ml of 22 and 40, histone H4 was observed in a variety of acetylation states, ranging from non-acetylated to tetra acetylated. These results support the notion that this compound series inhibits 15 HDACs. Further results are outlined in figure 2 for just compounds 40 and 73, showing hyperacetylation of H4. Once again, it was not necessary to quantitate histone deacetylation because the compounds inhibit HDAC activity in both normal and 20 cancer cells and has no impact on the cytoselectivity. The known HDAC inhibitor, TSA, included for comparison, showed similar levels of hyperacetylation indicated by the mobility shift of histone H4. Clearly visible in untreated cells in the non-acetylated histone H4 (lane 1, arrow A). In the extracts from cells treated with 10 Itg/ml of 40 and 73, histone H4 was observed 25 in a variety of acetylation states, ranging from non-acetylated to tetra acetylated. These results support the notion that this compound series inhibits HDACs. Induction of p21 Expression. It has been postulated that histone acetylation is 30 associated with activation of gene transcription. It has been shown that the action of HDAC inhibitors on gene expression is somewhat selective, and does not lead to global deregulation of transcription as may be expected. In cells cultured with TSA, the expression of only 2% of genes was significantly altered, indicating a remarkable specificity. Possibly the best characterised gene to be WO 2005/051901 PCT/AU2004/001667 107 induced following exposure to different HDAC inhibitors is that of the cyclin dependent kinase inhibitor p 21 WAF1/Cip1, which blocks cyclin-dependent kinase activity thereby causing cell-cycle arrest in G1. HDAC inhibitors are thought to act directly on the CDKN1A promoter rather than an upstream target. The 5 HDAC inhibitor SAHA induces accumulation of acetylated histones in the chromatin associated with the CDKNIA gene, and this correlates with the observed increase in transcription. Sp-1 transcription factor binding sites in the promoter of CDKN1A are considered to be crucial for the observed induction, and for a number of other targets. The capacity of novel compounds to induce 10 expression of the cyclin-dependent kinase inhibitor p2lWAF1/cip1 (CDKNIA) was examined by semi-quantitative RT-PCR after 8/24 hours of treatment in MM96L and NFF cell types. Cell Treatment and Total RNA Isolation. Cells were seeded in 25 cm 2 flasks 15 in 10% heat-inactivated foetal calf serum (CSL, Melbourne, Australia) in RPMI 1640 medium supplemented with 100 U/mL penicillin, 100 pg/rnL streptomycin, 3 mM HEPES, and incubated at 5% C0 2 , 99% humidity at 370C for 16 hours before treatment. Cells were treated with 10 pig/mL of drug and RNA harvested at the indicated times following treatment. Total RNA was extracted from cells 20 using the Qiagen RNeasy Kit as per manufacturer's instructions. RNA was analysed for sufficient quality by formamide agarose gel electrophoresis, and quantified by spectrophotometry. p21 Expression. The semi-quantitative analysis of mRNA expression of 25 p 21 WAF1/Cip1 was carried out by RT-PCR. First strand synthesis was performed using 2 pg total RNA with 0.5 tg oligo (dT) 1 5 and 200 U SuperScript II (Invitrogen, Carlsbad, CA), at 421C for 50 minutes in a final volume of 20 pLL. Polymerase chain reaction was performed using 10 pL of a 1 in 10 dilution of the first strand cDNA, under standard conditions with the polymerase 30 DyNAzyme (Finnzymes, Melbourne, Australia). Oligonucleotide primers and conditions used in the PCR were as follows: p 21 WAF1/Cip1 F 5'- ATT AGC AGC GGA ACA AGG AGT CAG ACA T -3', p 21 WAF1/cP1 R 5'- CTG TGA AAG ACA CAG AAC AGT ACA GGG T -3' with initial denaturation at 941C for 7 mins, 27 WO 2005/051901 PCT/AU2004/001667 108 cycles of 940C for 45 s, 600C for 40 s and 720C for 60 s, with the final extension for 5 minutes; GAPDH F 5'-GGC TCT CCA GAA CAT CAT CCC TGC-3', GAPDH R 5'-GGG TGT CGC TGT TGA AGT CAG AGG-3' with initial denaturation at 940C for 7 minutes, 25 cycles of 940C for 45 s, 620C for 40 s 5 and 720C for 60 s, with the final extension for 5 minutes. Products were analysed by agarose gel electrophoresis, and visualised on a UV light box. Product intensity was determined to increase linearly with number of cycles and amount of mRNA used, by densiometric analysis using ImageQuaNT 4.2 software (Molecular Dynamics, Sunnyvale, CA). Quantitation of p 2 1 WAF1Icip1 10 induction was also performed by densitometric analysis using ImageQuaNT 4.2 software following normalisation to GAPDH product intensity. Morphological Reversion. Cells were plated into 96-well microtitre plates at 5 x 103 cells / well, and allowed to adhere overnight. Compounds were added to 15 culture medium at the indicated concentrations, and plates incubated in the above conditions for 24 hours. Cells were then washed once with Hank's Balanced Salt Solution (HBSS; Gibco/Invitrogen, Grand Island, N.Y.), and fixed in 4% buffered formalin for 1 hour at room temperature. The fixed cells were then washed once further with HBSS and stained with 1% Crystal Violet in 20 methanol for 5 minutes. Excess stain was removed by washing with tap water, before the microtitre plate being air dried at 370C. Photographs were taken using a Leica DMIRB inverted microscope. Oral Biloavailability 25 Still the most effective form of drug delivery, in terms of ease of administration, probability of patient compliance, and systemic penetration, is the oral route which is the preferred form of delivery of antitumor drugs. Compounds of the invention were examined to see whether this new series had the expected favorable properties for oral delivery. The results indicate that the compound 30 series being developed here is, in general, orally bioavailable. Compound 24 (Log D 7 .o 2.7) was administered intravenously and orally to rats. When delivered at 5 mg/kg in 4:1 olive oil:DMSO to three rats starved prior to dosing, high serum levels of drug were maintained (Figure 7), with Cmax - 6 pg/mL for > 4 h WO 2005/051901 PCT/AU2004/001667 109 examined in this preliminary study and Tmax - 15 min. Neither vehicle nor fasting had any significant effects on these parameters. Finally, it will be appreciated that there may be other variations and 5 modifications to the methods described herein that are also within the scope of the present invention.

WO 2005/051901 PCT/AU2004/001667 110 References Marks, P. A., Richon, V. M., Kiyokawa, H., Rifkind, R. A. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. PNAS 5 (USA) 1994, 91, 10251-4 Rifkind, R. A., Richon, V. M., Marks, P. A. Induced differentiation, the cell cycle and the treatment of cancer. Pharmacol. Therap. 1996, 69, 97-102. 10 Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., Fisher P. B.; Differentiation therapy of human cancer: basic science and clinical implications. Pharnacol. Therap. 2001, 90, 105-156. Tsuji, N., Kobayashi, M., Nagashima, K., Wakisaka, Y., Koizumi, K. A new antifungal 15 antibiotic, trichostatin. J. Antibiot. 1976 29, 1-6. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specifik Inhibition of Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A. J. BioL Chem.1990, 265, 17174-17179. 20 Cress, W. D.; Seto, E. Histone Deacetylase, Transcriptional Control, and Cancer. J. Cell. Physiol. 2000, 184, 1-16. Marks, P.A. Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors 25 as new cancer drugs. Curr.Opin.Oncol. 2001, 13, 477-483.

WO 2005/051901 PCT/AU2004/001667 111 Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreverible Inhibitor of Mammalian Histone Deacetylase. J. Biol. Chem.1993, 268, 22429-22435. 5 Vigushin, D. M.; Coombes, R. C. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs. 2002, 13,1-13. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.: Yoshida, M.; Horinouchi, S. 10 Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. PNAS. 2001, 98, 87-92. Parsons, P.G., Bowman, E.P.W. and Blakely, R.L. Selective toxicity of deoxyadenosine analogues in human melanoma cell lines. Biochem. 15 Pharmacol. 1986, 35, 4025-4029. Todaro, G.J., Fryling, C. and De Larco, J.E. Transforming growth factors produced by certain human tumour cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 20 5258-5262. Glenn, M. P.; Kahnberg, P.; Boyle, G. M.; Hansford, K. A.; Hans, D.; Martyn, A. C.; Parsons, G. P.; Fairlie, D. P. Anti-Proliferative And Phenotype-Transforming Antitumor Agents Derived From Cysteine J. Med. Chem. 2004, 47, 2984-2994. 25

Claims (81)

1. A compound having the formula (I), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof: R 6 o R7-X' N 5 Z-R 1 -M (I) wherein 10 Z is S or CH 2 ; R 1 is a linking moiety; M is a zinc binding moiety containing at least one heteroatom; 15 R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; 20 X is selected from the group consisting of: 0 S 0 -CH 2 - -C- -C- and -S Y is selected from the group consisting: of -NR 4 R 5 , -OR 4 , -SR 4 , -CH 2 R 4 , 25 CHR 4 R 5 , C(R 4 ) 2 R 5 , PHR 4 and PR 4 R 5 , wherein R 4 is a group of formula: WO 2005/051901 PCT/AU2004/001667 113 /0H r(R)p-(R 9 )qf -N /(R1) wherein R 8 , R 9 and R 10 are each independently selected from the group 5 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; 10 p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1; R 5 is H or a group of formula: (R1I1)t- (R 12)u C-N (R 13)w, 15v wherein R 11 , R 12 and R 113 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, 20 optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1; 25 R 7 is a group of formula: (R16)z-(R13)y-(R14)x 30 wherein R 14 , R 1 5 and R 1 6 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, WO 2005/051901 PCT/AU2004/001667 114 optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl, 5 x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1.

2. A compound as in claim 1, wherein the zinc binding moiety is a group of formula -C(O)-NR 2 -OR 3 where R 2 is H, optionally substituted alkyl, optionally 10 substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group and R 3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group. 15

3. A compound as in claim 2, wherein the linking moiety has between 1 and 9 atoms in the normal chain.

4. A compound as in claim 3, wherein the linking moiety has between I and 4 atoms in the normal chain. 20

5. A compound as in claim 4, wherein the linking moiety is an n-propyl chain.

6. A compound having the formula (Illa), or a pharmaceutically acceptable 25 derivative, salt, racemate, isomer or tautomer thereof: F 6 0 R7N X'N NR 5 R4 SOR __ /0R R--C(O)-N R2 (Illla) WO 2005/051901 PCT/AU2004/001667 115 wherein R 1 is optionally substituted C-C 4 alkyl, optionally substituted Cl-C 4 5 alkenyl or optionally substituted C-C 4 alkynyl; R 2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group; 10 R 3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group; 15 R 4 is a group of formula: O0 H\ S(Rs)p-(R 9 )qfC-N r(Rio), wherein R 8 , R 9 and R 10 are each independently selected from the group 20 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; 25 p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1; R 5 is H or a group of formula: O0 H\ (RI11)t- (R12)u C-N (R13)w 30 WO 2005/051901 PCT/AU2004/001667 116 wherein R 1 1 , R 1 2 and R 1 1 3 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally 5 substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1. 10 R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; X is selected from the group consisting of 15 0 S 0 -CH2-~ -C- -C- and R 7 is a group of formula: 20 (R16)z-(R15)y-(R14)x wherein R 1 4 , R 15 and R 16 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally 25 substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl; x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1. 30 WO 2005/051901 PCT/AU2004/001667 117

7. A compound as in claim 6, wherein R, is optionally substituted C 1 -C 4 alkyl. 5

8. A compound as in claim 7, wherein R 1 is n-propyl.

9. A compound as in claim 6, wherein R 2 is either H, optionally substituted C-C 4 alkyl or a nitrogen protecting group.

10 10. A compound as in claim 9, wherein R 2 is H.

11. A compound as in claim 6, wherein R 3 is either H, optionally substituted CI-C 4 alkyl or an oxygen protecting group. 15

12. A compound as in claim 11, wherein R 3 is H.

13. A compound as in claim 6, wherein R 4 is of the formula: O H || 1 -R 8 -R 9 -C-N-R 1 0 , 20 wherein R 8 , R 9 and R 10 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted 25 heterocycloalkyl.

14. A compound as in claim 13, wherein R 4 is of the formula: O H ll 1 -(optionally substituted alkyl)-(optionally substituted aryl)-C-N-(optionally substituted aryl) 30

15. A compound as in claim 14, wherein R 4 is a group of the formula. WO 2005/051901 PCT/AU2004/001667 118 (R)n (R) -CH2-- N wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, 5 haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, 10 dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate 15 and phosphate; n is 0-4, and m is 0-5. 20

16. A compound as in claim 13, wherein R 4 has one of the following formulae: (R)m (R)m (R)m -alkyl -alkyl H (R)m (R)m (R)m Ret -alkenyl -alkenyl t 25 WO 2005/051901 PCT/AU2004/001667 119 wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, 5 cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, 10 arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphnyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; 15 and each m is from 0-5.

17. A compound as in claim 6, wherein R 5 is either H or optionally substituted alkyl. 20

18. A compound as in claim 17, wherein R 5 is H.

19. A compound as in claim 6, wherein X is a carbonyl group.

20. A compound as in claim 19, wherein R 6 is either H or a nitrogen 25 protecting group.

21. A compound as in claim 20, wherein R 6 is H.

22. A compound as in claim 19, wherein R 7 is selected from the group 30 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heteroaryl alkyl, optionally substituted cycloalkyl alkyl, optionally substituted WO 2005/051901 PCT/AU2004/001667 120 heterocycloalkyl alkyl, optionally substituted aryl alkenyl, optionally substituted hetero alkenyl, optionally substituted cycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted aryl alkynyl, optionally substituted heteroaryl alkynyl, optionally substituted cycloalkyl alkynyl, and 5 optionally substituted heterocycloalkyl alkynyl.

23. A compound as in claim 22, wherein R 7 has one of the following formula: (R)p (R)p (R)p alkyl He alkyl alkenyl-- Ht alkenyl HetHe 10 wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, 15 haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, 20 diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; 25 and each p is from 0-5. WO 2005/051901 PCT/AU2004/001667 121

24. A compound as in claim 6, wherein the compound has a potency of cytotoxicity of IC5o 10 pM against MM96 melanoma cells.

25. A compound as in claim 24, wherein the compound has a Selectivity 5 Index of 1.5.

26. A compound as in claim 25, wherein the compound has a potency of IC5o 1 tM against the MM96 melanoma cells and a Selectivity Index of 3. 10

27. A compound as in claim 26, wherein the compound has a potency of IC50 0.5 pM against the MM96 melanoma cells and a Selectivity Index of 4.

28. A compound having the formula (IlIb), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof: 15 R 6 o R7 X N R NH-OH 0 (Illb) 20 wherein R 1 is optionally substituted CrC4 alkyl, optionally substituted C1-C4 alkenyl or optionally substituted CrC4 alkynyl; 25 R 2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group; WO 2005/051901 PCT/AU2004/001667 122 R 3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group; 5 R 4 is a group of formula: O0 H\ r(R 8 )p-(R 9 )qC-N (R10), wherein R 8 , R 9 and R 10 are each independently selected from the group 10 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; 15 p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1; R 5 is H or a group of formula: O H (R 1 1)t-(R12)u C-N (R13)w 20v wherein R 11 , R 1 2 and R 113 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, 25 optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1. 30 WO 2005/051901 PCT/AU2004/001667 123 R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; 5 X is selected from the group consisting of 0 S 0 -CH2- -C- -C- and S R 7 is a group of formula: 10 (R16)z-(RI5)Y-(R14)x wherein R 14 , R 1 5 and R 1 6 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, 15 optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl; x, y and z are independently 0 and 1 with the proviso that at least one of 20 x,yand zis1.

29. A compound as in claim 28, wherein R 1 is optionally substituted C1-C4 alkyl. 25

30. A compound as in claim 29, wherein R 1 is n-propyl.

31. A compound as in claim 28, wherein R 2 is either H, optionally substituted C1-C4 alkyl or a nitrogen protecting group. 30 WO 2005/051901 PCT/AU2004/001667 124

32. A compound as in claim 31, wherein R 2 is H.

33. A compound as in claim 28, wherein R 3 is either H, optionally substituted C1C4 alkyl or an oxygen protecting group. 5

34. A compound as in claim 33, wherein R 3 is H.

35. A compound as in claim 28, wherein R 4 is of the formula: O H 10 -R 8 -R 9 -C-N-RIO wherein R 8 , R 9 and R 10 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally 15 substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.

36. A compound as in claim 35, wherein R 4 is of the formula: O H 20 -(optionally substituted alkyl)-(optionally substituted aryl)-C-N- (optionally substituted aryl)

37. A compound as in claim 36, wherein R 4 is a group of the formula. (R)n (R)m -CH2 0 -- N 25 wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, WO 2005/051901 PCT/AU2004/001667 125 cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, 5 diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; 10 n is 0-4, and m is 0-5. 15

38. A compound as in claim 35, wherein R 4 has one of the following formulae: (R)m (R)m (R)m -alkyl -alkyl H (R)m (R)m (R)m Ile -alkenyl -alkenyl He 20 wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, 25 haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, WO 2005/051901 PCT/AU2004/001667 126 diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphnyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate 5 and phosphate; and each m is from 0-5.

39. A compound as in claim 28, wherein R 5 is either H or optionally 10 substituted alkyl.

40. A compound as in claim 39, wherein R 5 is H.

41. A compound as in claim 28, wherein X is a carbonyl group. 15

42. A compound as in claim 41, wherein R 6 is either H or a nitrogen protecting group.

43. A compound as in claim 42, wherein R 6 is H. 20

44. A compound as in claim 41, wherein R 7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted 25 heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heteroaryl alkyl, optionally substituted cycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted aryl alkenyl, optionally substituted hetero alkenyl, optionally substituted cycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted aryl alkynyl, optionally 30 substituted heteroaryl alkynyl, optionally substituted cycloalkyl alkynyl, and optionally substituted heterocycloalkyl alkynyl.

45. A compound as in claim 44, wherein R 7 has one of the following formula: WO 2005/051901 PCT/AU2004/001667 127 (R)p (R)p (R)p alkyl -- alkyl (R~p(R)p (R)p alkenyl- alkenyl wherein each R is independently selected from the group consisting of alkyl, 5 alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, 10 nitroaryl, nitroheteroaryl, nitroheterocyclyoalky, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, 15 carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; and each p is from 0-5. 20

46. A compound as in claim 28, wherein the compound has a potency of cytotoxicity of IC50 10 pM against MM96 melanoma cells.

47. A compound as in claim 46, wherein the compound has a Selectivity Index of 1.5. 25

48. A compound as in claim 47, wherein the compound has a potency of IC50 1 1 M against the MM96 melanoma cells and a Selectivity Index of 3. WO 2005/051901 PCT/AU2004/001667 128

49. A compound as in claim 48, wherein the compound has a potency of IC50 0.5 ptM against the MM96 melanoma cells and a Selectivity Index of 4. 5

50. A method for the treatment of cancer in an animal, the method including the step of administering to the animal in need of such treatment an effective amount of a compound having the formula (I), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof: R 6 o R 7 - N 10 Z-R 1 -M (I) wherein 15 Z is S or -CH 2 -; R 1 is a linking moiety; M is a zinc binding moiety containing at least one heteroatom; 20 R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; 25 X is selected from the group consisting of: O S 0 -C- -C- and -S 0 WO 2005/051901 PCT/AU2004/001667 129 Y is selected from the group consisting: of -NR 4 R 5 , -OR 4 , -SR 4 , -CH 2 R 4 , CHR 4 R 5 , C(R 4 ) 2 R 5 , PHR 4 and PR 4 R 5 , 5 wherein R 4 is a group of formula: O0 H\ 1 (R 8 )p-(R 9 )qC-N r (R 1 o), wherein R 8 , R 9 and R1 0 are each independently selected from the group 10 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; 15 p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1; R 5 is H or a group of formula: O0 H\ 20 (R 1 1)t-(R12)u C-N ( wherein R11, R 12 and R 113 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, 25 optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1; 30 R 7 is a group of formula: WO 2005/051901 PCT/AU2004/001667 130 (RlE)z-(R15)y-(R14)xC wherein R 1 4 , R 1 5 and R 16 are independently selected from the group 5 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl, 10 x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1.

51. A method as in claim 50, wherein the linking moiety has between 1 and 9 atoms in the normal chain. 15

52. A method as in claim 51, wherein the linking moiety has between 1 and 4 atoms in the normal chain.

53. A method as in claim 52, wherein the linking moiety is an n-propyl chain. 20

54. A method for the treatment of cancer in an animal, the method including the step of administering to the animal in need of such treatment an effective amount of a compound having the formula (Ill), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof: 25 R 6 0 R7 ,,N N R5 R4 Z-R 1 -C(O)-N-OR 3 R-2 (Ill) wherein 30 Z is S or CH 2 ; WO 2005/051901 PCT/AU2004/001667 131 R, is optionally substituted C 1 -C 4 alkyl, optionally substituted C-C 4 alkenyl or optionally substituted Cr1C4 alkynyl; 5 R 2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group; R 3 is H, optionally substituted alkyl, optionally substituted alkenyl, 10 optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group; R 4 is a group of formula: 1 (R 8 )p-(R 9 )(C -N r (R 1 O)s 15 wherein Ra, R 9 and R 10 are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally 20 substituted heterocycloalkyl; p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1; 25 R 5 is H or a group of formula: O0 H (R11)t-(R12)u C-N v (R13)w wherein R 11 , R 1 2 and R 11 3 are each independently selected from the 30 group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, WO 2005/051901 PCT/AU2004/001667 132 optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; t, u, v and w are each independently 0 or 1, provided that at least one of 5 t, u and w is 1; R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group; 10 X is selected from the group consisting of O S 0 || || II -CH2 - C- and -S 0 15 R 7 is a group of formula: (Rj6)z-(R15)y-(R14)x wherein R 1 4 , R 15 and R 1 6 are independently selected from the group 20 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl, 25 x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1.

55. A method for the treatment of cancer as in claim 54, wherein R, is optionally substituted C1-C 4 alkyl. 30 WO 2005/051901 PCT/AU2004/001667 133

56. A method for the treatment of cancer as in claim 55, wherein R 1 is propyl.

57. A method for the treatment of cancer as in claim 54, wherein R 2 is either H, optionally substituted CrC4 alkyl or a nitrogen protecting group. 5

58. A method for the treatment of cancer as in claim 57, wherein R 2 is a nitrogen protecting group.

59. A method for the treatment of cancer as in claim 57, wherein R 2 is H. 10

60. A method for the treatment of cancer as in claim 54, wherein R 3 is either H, optionally substituted C1C4 alkyl or an oxygen protecting group.

61. A method for the treatment of cancer as in claim 60, wherein R 3 is an 15 oxygen protecting group.

62. A method for the treatment of cancer as in claim 60, wherein R 3 is H.

63. A method for the treatment of cancer as in claim 54, wherein R 4 is of the 20 formula: O H -R-R 9 -C-N-R 1 0 , wherein R 8 , R 9 and R 1 0 are each independently selected from the group 25 consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl. 30

64. A method for the treatment of cancer as in claim 63, wherein R 4 is of the formula: WO 2005/051901 PCT/AU2004/001667 134 O H -(optionally substituted alkyl)- (optionally substituted aryl)-C-N-(optionally substituted aryl)

65. A method for the treatment of cancer as in claim 64, wherein R 4 is a group of the formula. 5 (R)n (R)m -CH- 2 C-N wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, 10 haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, 15 dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate 20 and phosphate; n is 0-4, and m is 0-5. 25

66. A method for the treatment of cancer as in claim 64, wherein R 4 has one of the following formulas: WO 2005/051901 PCT/AU2004/001667 135 (R)m (R)m (R)m -alkyl -alkyl e (R), (R)m (R)m Ret -alkenyl -alkenyl e wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, 5 haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalky, amino, alkylamino, 10 dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphnyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate 15 and phosphate; and each m is from 0-5.

67. A method for the treatment of cancer as in claim 54, wherein R 5 is either 20 H or optionally substituted alkyl.

68. A method for the treatment of cancer as in claim 67, wherein R 5 is H.

69. A method for the treatment of cancer as in claim 54, wherein X is a 25 carbonyl group. WO 2005/051901 PCT/AU2004/001667 136

70. A method for the treatment of cancer as in claim 69, wherein R 6 is either H or a nitrogen protecting group.

71. A method for the treatment of cancer as in claim 70, wherein R 6 is H. 5

72. A method for the treatment of cancer as in claim 69, wherein R 7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally 10 substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heteroaryl alkyl, optionally substituted cycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted aryl alkenyl, optionally substituted hetero alkenyl, optionally substituted cycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted aryl alkynyl, 15 optionally substituted heteroaryl alkynyl, optionally substituted cycloalkyl alkynyl, and optionally substituted heterocycloalkyl alkynyl.

73. A method for the treatment of cancer as in claim 72, wherein R 7 has one of the following formula: 20 (R)p (R)p (R)p alkyl - - alkyl (R)p (R)p (R)p alkenyl- & - alkenyl wherein each R is independently selected from the group consisting of alkyl, 25 alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, WO 2005/051901 PCT/AU2004/001667 137 cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, 5 diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate; 10 and each p is from 0-5.

74. A method for the treatment of cancer as in claim 54, wherein the compound has a potency of cytotoxicity of IC50 10 tM against MM96 15 melanoma cells.

75. A method for the treatment of cancer as in claim 74, wherein the compound has a Selectivity Index of 1.5. 20

76. A method for the treatment of cancer as in claim 75, wherein the compound has a potency of ICgo 1 iM against the MM96 melanoma cells and a Selectivity Index of 3.

77. A method for the treatment of cancer as in claim 76, wherein the 25 compound has a potency of IC50 0.5 pM against the MM96 melanoma cells and a Selectivity Index of 4.

78. A method for the treatment of cancer as in claim 54, wherein the animal is a human. 30

79. A pharmaceutical composition containing one or more of the compounds of any one of claims 1 to 49 and a pharmaceutically acceptable, carrier, diluent or excipient. WO 2005/051901 PCT/AU2004/001667 138

80. The use of a compound of any one of claims 1 to 49 for the preparation of a medicament for the treatment of cancer.

81. A compound according to claim 1 and substantially as hereinbefore 5 described with reference to the accompanying examples. DATED: 26 November 2004 PHILLIPS ORMONDE & FITZPATRICK 10 Attorneys for: The University of Queensland